[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 332
1. Chaiyasate K, Jain AK, Cheung LY, Jacobs MJ, Mittal VK: Prognostic factors in primary adenocarcinoma of the small intestine: 13-year single institution experience. World J Surg Oncol; 2008;6:12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in primary adenocarcinoma of the small intestine: 13-year single institution experience.
  • BACKGROUND: Adenocarcinoma of the small bowel is a relatively rare malignancy as compared to the other malignancies of the gastrointestinal tract.
  • Nonspecific presentation and infrequent occurrence often leads to a delay in diagnosis and consequent poor prognosis.
  • METHODS: The medical records of a total of 27 patients treated for adenocarcinoma of the small bowel at Providence Hospital and Medical Centers from year 1990 through 2003 were reviewed retrospectively.
  • RESULTS: The patients included nine males and eighteen females with a median age at diagnosis of 62 years.
  • Only 48% of the patients had an accurate preoperative diagnosis while another 33% had a diagnosis suspicious of small bowel malignancy.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Intestinal Neoplasms / mortality. Intestinal Neoplasms / surgery. Intestine, Small / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Dec 15;86(12):2693-706 [10594865.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Arch Surg. 2000 Jun;135(6):635-41; discussion 641-2 [10843358.001]
  • [Cites] Arch Surg. 2000 Sep;135(9):1070-4; discussion 1074-5 [10982512.001]
  • [Cites] Hepatogastroenterology. 2001 May-Jun;48(39):727-32 [11462914.001]
  • [Cites] Gut. 2002 May;50(5):636-41 [11950808.001]
  • [Cites] J Gastrointest Surg. 2003 Nov;7(7):925-30 [14592670.001]
  • [Cites] Hepatogastroenterology. 2003 Dec;50 Suppl 2:ccxvi-ccxviii [15244183.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):518-26 [15274064.001]
  • [Cites] Ann Surg. 1974 Aug;180(2):175-9 [4843046.001]
  • [Cites] Ann Surg. 1979 Jun;189(6):732-40 [453945.001]
  • [Cites] Am J Surg. 1980 Sep;140(3):396-9 [7425215.001]
  • [Cites] Am J Surg. 1981 Nov;142(5):569-73 [7304812.001]
  • [Cites] Am J Surg. 1984 Jan;147(1):66-71 [6691554.001]
  • [Cites] Surg Clin North Am. 1986 Aug;66(4):779-85 [3738698.001]
  • [Cites] Am J Surg. 1987 Apr;153(4):350-4 [3565678.001]
  • [Cites] Cancer. 1990 Aug 15;66(4):702-15 [2167140.001]
  • [Cites] Br J Cancer. 1991 Jan;63(1):143-5 [1989654.001]
  • [Cites] Am J Gastroenterol. 1991 Mar;86(3):304-8 [1998312.001]
  • [Cites] Dig Dis Sci. 1992 Aug;37(8):1179-84 [1499440.001]
  • [Cites] Am J Surg. 1993 Dec;166(6):626-30; discussion 630-1 [7903846.001]
  • [Cites] Gastroenterology. 1996 Feb;110(2):459-68 [8566593.001]
  • [Cites] Ann Surg. 1997 Mar;225(3):300-6 [9060587.001]
  • [Cites] Cancer. 1998 Jul 15;83(2):240-4 [9669805.001]
  • [Cites] Dig Surg. 1998;15(1):42-51 [9845562.001]
  • [Cites] N Engl J Med. 1959 Feb 26;260(9):397-408 [13632900.001]
  • [Cites] Arch Surg. 1965 Sep;91:452-5 [14332400.001]
  • [Cites] World J Surg. 2000 Apr;24(4):421-9 [10706914.001]
  • (PMID = 18237404.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2253527
  •  go-up   go-down


2. Dasari BV, Gardiner KR: Management of adenocarcinoma of the small intestine. Gastrointest Cancer Res; 2009 May;3(3):121-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of adenocarcinoma of the small intestine.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Gastroenterol Hepatol. 2008 Jun;6(6):671-6 [18356113.001]
  • [Cites] World J Surg Oncol. 2008;6:12 [18237404.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2008;22(5):789-811 [18790433.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2008;22(5):813-37 [18790434.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Nov;6(11):1202-5 [18799359.001]
  • [Cites] Gut. 2008 Nov;57(11):1631-2 [18941013.001]
  • [Cites] Ann Epidemiol. 2009 Jan;19(1):58-69 [19064190.001]
  • [Cites] J Clin Oncol. 2009 Jun 1;27(16):2598-603 [19164203.001]
  • [Cites] Radiology. 2009 Jun;251(3):743-50 [19304922.001]
  • [Cites] Gastrointest Cancer Res. 2009 May;3(3):90-6 [19626152.001]
  • [Cites] Am J Gastroenterol. 1991 Mar;86(3):304-8 [1998312.001]
  • [Cites] Lancet. 1983 Jan 15;1(8316):111-5 [6129425.001]
  • [Cites] Gastroenterology. 2000 Dec;119(6):1447-53 [11113065.001]
  • [Cites] Eur J Surg Oncol. 2002 Feb;28(1):19-23 [11869008.001]
  • [Cites] Radiology. 2004 Nov;233(2):338-44 [15459329.001]
  • [Cites] J Surg Oncol. 2005 Aug 1;91(2):112-7; discussion 118-9 [16028284.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):22-7 [16736516.001]
  • [Cites] Surg Clin North Am. 2007 Jun;87(3):587-610 [17560414.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1436-41 [17689032.001]
  • [Cites] Surg Endosc. 2009 Apr;23(4):739-44 [18622544.001]
  • (PMID = 19626156.001).
  • [ISSN] 1934-7820
  • [Journal-full-title] Gastrointestinal cancer research : GCR
  • [ISO-abbreviation] Gastrointest Cancer Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2713137
  •  go-up   go-down


3. Overman MJ, Pozadzides J, Kopetz S, Wen S, Abbruzzese JL, Wolff RA, Wang H: Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. Br J Cancer; 2010 Jan 5;102(1):144-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine.
  • BACKGROUND: Despite having a dramatically larger surface area than the large intestine, the small intestine is an infrequent site for the development of adenocarcinoma.
  • To better understand the molecular abnormalities in small bowel adenocarcinoma (SBA), we characterised a number of candidate oncogenic pathways and the immunophenotype of this rare cancer.
  • CONCLUSIONS: These results suggest that alterations in DNA MMR pathways are common in SBAs, similar to what is observed in large bowel adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Duodenal Neoplasms / genetics. Gene Expression Profiling. Immunophenotyping. Neoplasm Proteins / biosynthesis. Oncogenes

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Dec 15;86(12):2693-706 [10594865.001]
  • [Cites] Arch Pathol Lab Med. 2007;131(1):18-43 [19548375.001]
  • [Cites] N Engl J Med. 2000 Jan 13;342(2):69-77 [10631274.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):870-6 [10843291.001]
  • [Cites] Endocr Relat Cancer. 2000 Jun;7(2):115-29 [10903528.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] Food Chem Toxicol. 2001 Mar;39(3):209-28 [11278053.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1331-46 [11571750.001]
  • [Cites] Brain Pathol. 2002 Jan;12(1):95-107 [11770905.001]
  • [Cites] Oncogene. 2002 Jan 3;21(1):158-64 [11791187.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):439-47 [12163369.001]
  • [Cites] Eur J Cancer. 2002 Nov;38(17):2258-64 [12441262.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):303-10 [12604886.001]
  • [Cites] Cancer. 2003 Mar 15;97(6):1551-7 [12627520.001]
  • [Cites] Mod Pathol. 2003 May;16(5):403-10 [12748245.001]
  • [Cites] Mod Pathol. 2003 Sep;16(9):913-9 [13679455.001]
  • [Cites] Cancer Lett. 2004 Jan 20;203(2):181-90 [14732226.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):261-8 [14970275.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3014-21 [15126336.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):712-8 [15166663.001]
  • [Cites] Br J Cancer. 2004 Jul 19;91(2):355-8 [15188009.001]
  • [Cites] Am J Surg Pathol. 2004 Oct;28(10):1352-9 [15371952.001]
  • [Cites] Nat Genet. 1995 Jan;9(1):48-55 [7704024.001]
  • [Cites] Jpn J Cancer Res. 1995 Apr;86(4):357-60 [7775257.001]
  • [Cites] J Surg Oncol. 1996 Feb;61(2):100-5 [8606540.001]
  • [Cites] Dig Dis. 1996 Jul-Aug;14(4):245-57 [8843980.001]
  • [Cites] Mod Pathol. 1996 Nov;9(11):1040-4 [8933513.001]
  • [Cites] Gastroenterology. 1997 Jul;113(1):127-35 [9207270.001]
  • [Cites] Cell. 1998 Oct 2;95(1):29-39 [9778245.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3346-51 [10416591.001]
  • [Cites] Mod Pathol. 2006 Apr;19(4):573-80 [16501564.001]
  • [Cites] Br J Surg. 2006 Nov;93(11):1424-32 [17022010.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):48-56 [17631130.001]
  • [Cites] Am J Clin Pathol. 2007 Nov;128(5):808-16 [17951204.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14(20):6371-5 [18927275.001]
  • [Cites] Cancer Cell. 2009 Mar 3;15(3):220-31 [19249680.001]
  • [CommentIn] Br J Cancer. 2010 Oct 12;103(8):1305; author reply 1306 [20842127.001]
  • (PMID = 19935793.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / Neoplasm Proteins; 68238-35-7 / Keratins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Other-IDs] NLM/ PMC2813754
  •  go-up   go-down


Advertisement
4. von Rahden BH, Brücher BL, Langner C, Siewert JR, Stein HJ, Sarbia M: Expression of cyclo-oxygenase 1 and 2, prostaglandin E synthase and transforming growth factor beta1, and their relationship with vascular endothelial growth factors A and C, in primary adenocarcinoma of the small intestine. Br J Surg; 2006 Nov;93(11):1424-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cyclo-oxygenase 1 and 2, prostaglandin E synthase and transforming growth factor beta1, and their relationship with vascular endothelial growth factors A and C, in primary adenocarcinoma of the small intestine.
  • BACKGROUND: Primary adenocarcinomas of the small intestine are rare.
  • METHODS: Expression of cyclo-oxygenase (COX) 1 and 2, prostaglandin E synthase (PGES), TGF-beta1 and vascular endothelial growth factor (VEGF) A and C genes was analysed in 54 primary adenocarcinomas of the small intestine and corresponding normal intestinal mucosa.
  • COX-1, COX-2, VEGF-A, VEGF-C, PGES and TGF-beta1 mRNA expression varied markedly in different tumours, but all were overexpressed compared with levels in normal intestinal mucosa.
  • CONCLUSION: Correlations between levels of mRNA for COX-1, COX-2, TGF-beta1 and PGES and those for proangiogenic factors VEGF-A and VEGF-C suggest a role for these factors in the propagation of primary adenocarcinomas of the small intestine.
  • [MeSH-major] Adenocarcinoma / metabolism. Ileal Neoplasms / metabolism. Neoplasm Proteins / metabolism. Prostaglandin-Endoperoxide Synthases / metabolism. Transforming Growth Factor beta1 / metabolism. Vascular Endothelial Growth Factors / metabolism

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17022010.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Transforming Growth Factor beta1; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factor C; 0 / Vascular Endothelial Growth Factors; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


5. Hong SH, Koh YH, Rho SY, Byun JH, Oh ST, Im KW, Kim EK, Chang SK: Primary adenocarcinoma of the small intestine: presentation, prognostic factors and clinical outcome. Jpn J Clin Oncol; 2009 Jan;39(1):54-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adenocarcinoma of the small intestine: presentation, prognostic factors and clinical outcome.
  • BACKGROUND: Malignant small intestine tumor accounts for 0.1-0.3% of all malignancies.
  • Although primary adenocarcinoma is the most common histologic subtype, there is no report of the clinical characteristics and natural history in the Asian population.
  • METHODS: We conducted retrospective analysis for the patients with the small intestine adenocarcinoma to explore the clinical characteristics and prognosis.
  • All patients with adenocarcinoma of small intestine diagnosed between March 1997 and March 2007 in the Catholic Medical Center in Korea were identified through the cancer registry.
  • CONCLUSIONS: The prognosis of primary adenocarcinoma of small intestine was poor, especially in cases where curative resection could not to be performed.
  • [MeSH-major] Adenocarcinoma / pathology. Intestinal Neoplasms / pathology. Intestine, Small / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Korea. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18997182.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


6. Lugli A, Spichtin H, Maurer R, Mirlacher M, Kiefer J, Huusko P, Azorsa D, Terracciano L, Sauter G, Kallioniemi OP, Mousses S, Tornillo L: EphB2 expression across 138 human tumor types in a tissue microarray: high levels of expression in gastrointestinal cancers. Clin Cancer Res; 2005 Sep 15;11(18):6450-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: We found most prominent EphB2 expression in the intestinal epithelium (colonic crypts) with cancer of the colorectum displaying the highest EphB2 positivity of all tumors.
  • EphB2 expression was also observed in 75 tumor categories, including serous carcinoma of the endometrium (34.8%), adenocarcinoma of the esophagus (33.3%), intestinal adenocarcinoma of the stomach (30.2%), and adenocarcinoma of the small intestine (70%).
  • The occasional finding of strong EphB2 positivity in tumors without EphB2 positivity in the corresponding normal cells [adenocarcinoma of the lung (4%) and pancreas (2.2%)] suggests that deregulation of EphB2 signaling may involve up-regulation of the protein expression.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16166419.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, EphB2
  •  go-up   go-down


7. Overman MJ: Recent advances in the management of adenocarcinoma of the small intestine. Gastrointest Cancer Res; 2009 May;3(3):90-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent advances in the management of adenocarcinoma of the small intestine.
  • Adenocarcinoma of the small intestine is a rare malignancy with limited data available to guide therapeutic decisions.
  • Delays in diagnosis are frequent and the majority of patients will present with advanced-stage disease and either lymph node involvement or distant metastatic disease.
  • Recent retrospective and prospective studies have helped to clarify the optimal chemotherapy approach for advanced small bowel adenocarcinoma.
  • This article reviews the clinical features and evaluation of patients with small bowel adenocarcinoma and focuses on recent advances in management.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Today. 2009;39(1):27-31 [19132464.001]
  • [Cites] Arch Surg. 2000 Jun;135(6):635-41; discussion 641-2 [10843358.001]
  • [Cites] Ann Surg. 2009 Jan;249(1):63-71 [19106677.001]
  • [Cites] Cancer Res. 2008 Nov 15;68(22):9274-9 [19010900.001]
  • [Cites] Gastroenterology. 2008 Oct;135(4):1163-7 [18727930.001]
  • [Cites] Cancer. 2008 Oct 15;113(8):2038-45 [18759326.001]
  • [Cites] Dig Dis Sci. 2008 Aug;53(8):2140-3 [18270840.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1436-41 [17689032.001]
  • [Cites] Ann Surg Oncol. 2007 Aug;14(8):2263-9 [17549572.001]
  • [Cites] Arch Surg. 2007 Mar;142(3):285-8 [17372054.001]
  • [Cites] Radiology. 2006 Dec;241(3):796-801 [17053201.001]
  • [Cites] Gastrointest Endosc. 2006 Sep;64(3):445-9 [16923502.001]
  • [Cites] Am J Clin Oncol. 2006 Jun;29(3):225-31 [16755174.001]
  • [Cites] World J Surg. 2006 Mar;30(3):391-8; discussion 399 [16479330.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):209; author reply 209-10 [16382129.001]
  • [Cites] Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4 [10615932.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2693-706 [10594865.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3761-9 [12963697.001]
  • [Cites] J Chemother. 2003 Oct;15(5):503-6 [14598944.001]
  • [Cites] J Gastrointest Surg. 2003 Nov;7(7):925-30 [14592670.001]
  • [Cites] Cancer. 2003 Mar 15;97(6):1551-7 [12627520.001]
  • [Cites] Dis Colon Rectum. 2002 Nov;45(11):1496-502 [12432298.001]
  • [Cites] Arch Surg. 2002 May;137(5):564-70; discussion 570-1 [11982470.001]
  • [Cites] Gut. 2002 Feb;50(2):218-23 [11788563.001]
  • [Cites] Oncology. 2005;69(4):290-4 [16282708.001]
  • [Cites] Endoscopy. 2005 Oct;37(10):960-5 [16189768.001]
  • [Cites] Oncology. 2005;68(4-6):526-37 [16037686.001]
  • [Cites] Scand J Gastroenterol. 2005 Jun;40(6):725-33 [16036534.001]
  • [Cites] Oncologist. 2005 Feb;10(2):132-7 [15709215.001]
  • [Cites] Dig Liver Dis. 2004 Nov;36(11):782-3 [15571011.001]
  • [Cites] Surg Gynecol Obstet. 1956 Jan;102(1):1-38 [13299024.001]
  • [Cites] Am J Surg. 1965 Jan;109:43-6 [14248295.001]
  • [Cites] Scand J Gastroenterol. 2004 Aug;39(8):748-53 [15513360.001]
  • [Cites] Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):210-5 [9435876.001]
  • [Cites] Int J Cancer. 1999 Jul 19;82(2):171-4 [10389747.001]
  • [Cites] Br J Surg. 1999 Feb;86(2):189-93 [10100785.001]
  • [Cites] J Gastrointest Surg. 1998 Jan-Feb;2(1):79-87 [9841972.001]
  • [Cites] Br J Cancer. 1998 Aug;78(4):508-10 [9716035.001]
  • [Cites] Cancer. 1998 Jul 15;83(2):240-4 [9669805.001]
  • [Cites] J Comput Assist Tomogr. 1997 Nov-Dec;21(6):986-91 [9386295.001]
  • [Cites] Int J Cancer. 1997 Feb 7;70(4):390-5 [9033644.001]
  • [Cites] J Am Coll Surg. 1996 Aug;183(2):89-96 [8696551.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):3011-20 [8187091.001]
  • [Cites] Ann Surg Oncol. 1994 Jan;1(1):73-8 [7834432.001]
  • [Cites] Ann Surg Oncol. 1994 May;1(3):183-8 [7842287.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1993 Nov-Dec;2(6):551-3 [8268772.001]
  • [Cites] Gastrointest Radiol. 1991 Spring;16(2):115-9 [2016021.001]
  • [Cites] Am J Gastroenterol. 1991 Mar;86(3):304-8 [1998312.001]
  • [Cites] AJR Am J Roentgenol. 1989 Oct;153(4):741-4 [2672733.001]
  • [Cites] Cancer. 1990 Aug 15;66(4):702-15 [2167140.001]
  • [Cites] J Radiol. 1983 Feb;64(2):117-23 [6341573.001]
  • [Cites] Am J Surg. 1984 Jan;147(1):66-71 [6691554.001]
  • [Cites] Cancer. 1984 Jan 1;53(1):23-5 [6690001.001]
  • [Cites] Cancer. 1981 Aug 1;48(3):799-819 [7248908.001]
  • [Cites] Am J Surg. 1977 Sep;134(3):331-3 [900333.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):518-26 [15274064.001]
  • [Cites] J Clin Pathol. 2003 Dec;56(12):898-903 [14645346.001]
  • [Cites] Hepatogastroenterology. 2001 May-Jun;48(39):727-32 [11462914.001]
  • [Cites] Food Chem Toxicol. 2001 Mar;39(3):209-28 [11278053.001]
  • [Cites] Gastric Cancer. 2008;11(4):201-5 [19132481.001]
  • (PMID = 19626152.001).
  • [ISSN] 1934-7820
  • [Journal-full-title] Gastrointestinal cancer research : GCR
  • [ISO-abbreviation] Gastrointest Cancer Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2713134
  •  go-up   go-down


8. Namikawa T, Hanazaki K: Clinical analysis of primary anaplastic carcinoma of the small intestine. World J Gastroenterol; 2009 Feb 7;15(5):526-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical analysis of primary anaplastic carcinoma of the small intestine.
  • Primary anaplastic carcinoma is a rare variant of small intestinal cancer.
  • Most reports of primary anaplastic carcinoma of the small intestine are isolated case reports, therefore the clinicopathological features, therapeutic management, and surgical outcome of this tumor type remain unclear.
  • This review analyzes the available clinical characteristics of primary anaplastic carcinoma of the small intestine and investigates key differences from differentiated adenocarcinoma of the small intestine.
  • A Medline search was performed using the keywords 'small intestine' and 'anaplastic carcinoma' or 'undifferentiated carcinoma'.
  • The literature revealed a poor prognosis for patients who underwent surgical resection for anaplastic carcinoma of the small intestine, which gave a 3-year overall survival rate of 10.8% and a median survival time of 5.0 mo.
  • The literature suggests that anaplastic carcinoma is markedly more aggressive than differentiated adenocarcinoma of the small intestine.
  • Surgical resection with the aim of complete tumor removal provides the only beneficial therapeutic option for patients with anaplastic carcinoma of the small intestine, because chemotherapy and radiation therapy have no significant effect on the rate of survival.
  • However, despite complete tumor resection, most patients with anaplastic carcinoma of the small intestine are at great risk of disease recurrence.
  • This report also highlights the importance of a systematic diagnostic approach for anaplastic carcinoma of the small intestine.
  • [MeSH-major] Carcinoma / pathology. Intestinal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Intestinal Mucosa / pathology. Intestine, Small / pathology. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Survivors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2006 Mar;30(3):391-8; discussion 399 [16479330.001]
  • [Cites] World J Surg Oncol. 2008;6:12 [18237404.001]
  • [Cites] Surgery. 2000 Oct;128(4):604-12 [11015094.001]
  • [Cites] Gastrointest Endosc. 2001 Feb;53(2):216-20 [11174299.001]
  • [Cites] Arch Surg. 2002 May;137(5):564-70; discussion 570-1 [11982470.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):518-26 [15274064.001]
  • [Cites] Lancet. 1973 Jan 6;1(7793):24-6 [4118541.001]
  • [Cites] Ann Surg. 1974 Aug;180(2):157-61 [4842978.001]
  • [Cites] Ann Surg. 1979 Jun;189(6):732-40 [453945.001]
  • [Cites] Am J Surg. 1980 Sep;140(3):396-9 [7425215.001]
  • [Cites] Am J Surg. 1984 Jan;147(1):66-71 [6691554.001]
  • [Cites] Am J Surg. 1987 Apr;153(4):350-4 [3565678.001]
  • [Cites] Ann Surg. 1987 Dec;206(6):706-10 [3689007.001]
  • [Cites] Hum Pathol. 1989 Sep;20(9):858-63 [2777242.001]
  • [Cites] Gastroenterology. 1993 Dec;105(6):1716-23 [8253348.001]
  • [Cites] Ann Surg. 1997 Mar;225(3):300-6 [9060587.001]
  • [Cites] Am J Surg. 1997 Mar;173(3):237-9 [9124635.001]
  • [Cites] Oncology (Williston Park). 1997 Apr;11(4):529-36; discussion 545, 549-50 [9130275.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Mar;7(3):243-51 [9521441.001]
  • [Cites] J Am Coll Surg. 1998 Jun;186(6):664-8 [9632155.001]
  • [Cites] J Clin Gastroenterol. 1999 Jul;29(1):99-101 [10405244.001]
  • [Cites] Cancer Imaging. 2007;7:224-33 [18083648.001]
  • [Cites] Arch Surg. 2000 Jun;135(6):635-41; discussion 641-2 [10843358.001]
  • (PMID = 19195053.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2653339
  •  go-up   go-down


9. Ono M, Shirao K, Takashima A, Morizane C, Okita N, Takahari D, Hirashima Y, Eguchi-Nakajima T, Kato K, Hamaguchi T, Yamada Y, Shimada Y: Combination chemotherapy with cisplatin and irinotecan in patients with adenocarcinoma of the small intestine. Gastric Cancer; 2008;11(4):201-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy with cisplatin and irinotecan in patients with adenocarcinoma of the small intestine.
  • BACKGROUND: Small-bowel adenocarcinoma (SBA) is a rare tumor that has a poor response to chemotherapy and a poor prognosis.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Intestinal Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19132481.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


10. Overman MJ, Kopetz S, Lin E, Abbruzzese JL, Wolff RA: Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine. Acta Oncol; 2010 May;49(4):474-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine.
  • BACKGROUND: The benefit of adjuvant therapy for resected small bowel adenocarcinoma has not been proven.
  • We undertook a retrospective analysis to evaluate the benefit of adjuvant therapy in a clearly defined patient population with curatively resected small bowel adenocarcinoma.
  • MATERIAL AND METHODS: We identified 54 patients with small bowel adenocarcinoma who underwent margin-negative surgical resection and were evaluated after surgery at the University of Texas, M. D.
  • DISCUSSION: The use of adjuvant therapy for curatively resected small bowel adenocarcinoma was associated with an improvement in DFS.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Intestinal Neoplasms / therapy. Intestine, Small

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20397775.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


11. Chang HK, Yu E, Kim J, Bae YK, Jang KT, Jung ES, Yoon GS, Kim JM, Oh YH, Bae HI, Kim GI, Jung SJ, Gu MJ, Kim JY, Jang KY, Jun SY, Eom DW, Kwon KW, Kang GH, Park JB, Hong S, Lee JS, Park JY, Hong SM, Korean Small Intestinal Cancer Study Group: Adenocarcinoma of the small intestine: a multi-institutional study of 197 surgically resected cases. Hum Pathol; 2010 Aug;41(8):1087-96
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the small intestine: a multi-institutional study of 197 surgically resected cases.
  • Small intestinal adenocarcinoma is a rare malignant neoplasm, and its clinicopathologic characteristics have not been well elucidated.
  • A total of 197 small intestinal adenocarcinoma cases were collected from 22 institutions in South Korea and were evaluated for clinicopathologic factors that affect the prognosis of small intestinal adenocarcinoma patients using univariate and multivariate analyses.
  • The median survival time for all small intestinal adenocarcinoma patients was 39.7 months.
  • Compared with small intestinal adenocarcinomas without accompanying sporadic adenomas, small intestinal adenocarcinomas with accompanying adenomas were more well differentiated (P < .0001), with a more polypoid growth pattern (P < .0001), a lower pT classification (P < .0001), less perineural invasion (P = .01), and less lymphatic invasion (P = .03).
  • Small intestinal adenocarcinoma patients with associated sporadic adenomas (77%) had a significantly better 5-year survival rate than those without sporadic adenomas (38%, P = .02).
  • By univariate analysis, small intestinal adenocarcinoma patients had significantly different survival based on pT classification (P = .003), lymph node metastasis (P < .0001), distal location (jejunal and ileal carcinomas) (P = .003), retroperitoneal tumor seeding (P < .0001), vascular invasion (P = .007), lymphatic invasion (P = .001), peritumoral dysplasia (P = .004), and radiation therapy (P = .006).
  • In conclusion, (1) small intestinal adenocarcinomas are diagnosed at an advanced disease stage; therefore, the development of strategies for detection at an earlier stage is needed. (2) Small intestinal adenocarcinoma patients with an adenomatous component had a better survival than those without an adenomatous component. (3) Lymph node metastasis and distal location (jejunum and ileum) of tumor are the most important independent prognostic factors.
  • [MeSH-major] Adenocarcinoma / pathology. Duodenal Neoplasms / pathology. Ileal Neoplasms / pathology. Jejunal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Intestine, Small / pathology. Kaplan-Meier Estimate. Lymphatic Metastasis / pathology. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20334897.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Mastoraki A, Konstantiadou I, Papanikolaou I, Christodolou S, Sakorafas G, Peros G: Adenocarcinoma of the small intestine complicating Crohn's disease. Int J Colorectal Dis; 2009 Oct;24(10):1245-6
MedlinePlus Health Information. consumer health - Crohn's Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the small intestine complicating Crohn's disease.
  • [MeSH-major] Adenocarcinoma / complications. Crohn Disease / complications. Intestinal Neoplasms / complications
  • [MeSH-minor] Adult. Aged. Humans. Incidence. Intestinal Obstruction / complications. Male. Middle Aged. Spondylitis, Ankylosing / complications

  • Genetic Alliance. consumer health - Crohn Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19408004.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  •  go-up   go-down


13. Patel S, Liu D, Caron P, Seiter K: Acute myelogenous leukemia following irinotecan-based chemotherapy for adenocarcinoma of the small intestine. Leuk Lymphoma; 2007 May;48(5):1032-3
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myelogenous leukemia following irinotecan-based chemotherapy for adenocarcinoma of the small intestine.
  • [MeSH-major] Adenocarcinoma / drug therapy. Camptothecin / analogs & derivatives. Intestinal Neoplasms / drug therapy. Intestine, Small / pathology. Leukemia, Myeloid, Acute / drug therapy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17487750.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; IFL protocol
  •  go-up   go-down


14. Overman MJ, Hu C, Wolff RA, Chang GJ: Impact of lymph node evaluation on survival for small bowel adenocaricnoma: Analysis of the Surveillance, Epidemiology and End Results (SEER) database. J Clin Oncol; 2009 May 20;27(15_suppl):4596

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of lymph node evaluation on survival for small bowel adenocaricnoma: Analysis of the Surveillance, Epidemiology and End Results (SEER) database.
  • : 4596 Background: Small bowel adenocarcinoma is a rare malignancy and is often associated with poor outcome.
  • METHODS: Patients aged 18-90 with adenocarcinoma of the small intestine diagnosed between 1988 and 2005 were identified from SEER data (ver. 2008).
  • CONCLUSIONS: As noted in colon cancer, the total number of LN assessed has considerable influence upon survival in stage I, II and III small bowel adenocarcinoma.
  • Stratifying stage III small bowel adenocarcinoma into those with <3 and ≥3 positive lymph nodes significantly improves prognostication for these patients and future staging systems should incorporate the number of positive nodes into nodal staging.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963112.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Singhal N, Singhal D: Adjuvant chemotherapy for small intestine adenocarcinoma. Cochrane Database Syst Rev; 2007;(3):CD005202
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for small intestine adenocarcinoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy for small intestine adenocarcinoma.
  • BACKGROUND: Although the small intestine represents 75% of the length and over 90% of the mucosal surface of the alimentary tract, it is the site of only about 2% of malignant gastrointestinal tumours.
  • Adenocarcinoma is the most common histological subtype, accounting for about 40% of all malignant small intestinal tumours.
  • The consequences are a significant delay in diagnosis and the finding of advanced, incurable disease at operation.
  • The rare nature of adenocarcinomas of the small intestine has led to a paucity of information about the benefits of adjuvant chemotherapy but there are reports of overall better survival for those patients that receive combination treatment.
  • OBJECTIVES: To determine the role of adjuvant chemotherapy in the management of adenocarcinoma of the small intestine compared to another adjuvant treatment, a placebo or no other adjuvant treatment.
  • SELECTION CRITERIA: Phase III randomised controlled trials comparing post-operative adjuvant chemotherapy for adenocarcinoma of the small intestine with other adjuvant therapies, placebo or no adjuvant treatment.
  • AUTHORS' CONCLUSIONS: There is a need for high quality randomised controlled trials to evaluate the effectiveness of adjuvant chemotherapy in the management of adenocarcinoma of the small intestine.
  • [MeSH-major] Adenocarcinoma / drug therapy. Intestinal Neoplasms / drug therapy. Intestine, Small

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17636789.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 36
  •  go-up   go-down


16. Ogata Y, Yamaguchi K, Sasatomi T, Uchida S, Akagi Y, Shirouzu K: [Treatment and outcome in small bowel cancer]. Gan To Kagaku Ryoho; 2010 Aug;37(8):1454-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment and outcome in small bowel cancer].
  • In adenocarcinoma of the small intestine, delays in diagnosis are frequent, and the majority of patients present with advanced- stage disease and either lymph node involvement or distant metastatic disease.
  • Recent retrospective and prospective studies have helped to clarify the optimal chemotherapy approach for advanced small bowel adenocarcinoma.
  • The 72nd Japanese Society for Cancer of the Colon and Rectum have conducted a retrospective review of Japanese patients with adenocarcinoma of the jejunum or ileum.
  • The data indicated that although not statistically significant, there was a trend in median overall survival favoring the chemotherapy for advanced jejunal or ileal adenocarcinoma (17 months vs. 8 months, p=0.114).
  • [MeSH-major] Adenocarcinoma / therapy. Intestinal Neoplasms / therapy. Intestine, Small

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20716869.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 13
  •  go-up   go-down


17. Okubo K, Yoshioka S, Asukai K, Hata T, Nakanishi M, Maekawa T, Hama N, Kashiwazaki M, Taniguchi M, Tsujie M, Konishi M, Yano K, Fujimoto T: [A case report of primary adenocarcinoma of small intestine]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2792-4
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of primary adenocarcinoma of small intestine].
  • This is an account of a case of primary adenocarcinoma of the small intestine with peritoneal dissemination successfully treated with chemotherapy.
  • Abdominal computerized tomography revealed a bowel obstruction with tumor and the remarkable small bowel dilation of oral side of tumor.
  • Pathological diagnosis of the resected specimen was adenocarcinoma with lymph nodes metastasis.
  • The peritoneal dissemination consisted of metastatic adenocarcinoma from small intestine.
  • Primary small intestinal adenocarcinoma is a rare disease, and it is often diagnosed as advanced cancer because of few characteristic symptoms.
  • So carcinoma of the small intestine usually has a poor prognosis.
  • [MeSH-major] Adenocarcinoma / therapy. Intestinal Neoplasms / therapy

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224715.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Organoplatinum Compounds; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 2S9ZZM9Q9V / Bevacizumab; 5VT6420TIG / Oxonic Acid; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


18. Sugae T, Yaguchi T, Kajikawa M, Nakayama S, Takase T, Inokawa Y, Tsushima Y, Watanabe T, Harada A: [A case report of primary adenocarcinoma of small intestine successfully treated with FOLFOX]. Gan To Kagaku Ryoho; 2008 Nov;35(11):1969-71
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of primary adenocarcinoma of small intestine successfully treated with FOLFOX].
  • This is an account of a case of primary adenocarcinoma of the small intestine successfully treated with chemotherapy.
  • Abdominal computerized tomography revealed bowel obstruction, and this was found at surgery to be due to a tumor at the jejunum 100 cm distal from the Treitz ligament.
  • Pathological diagnosis of the resected specimen was adenocarcinoma.
  • Primary small intestinal adenocarcinoma is a rare disease with a dismal prognosis.
  • The current patient survived for 4 years and 5 months after the diagnosis, owing at least partially to the mFOLFOX6 which was found to be the only active regimen.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Intestinal Neoplasms / drug therapy. Intestinal Neoplasms / pathology. Intestine, Small / drug effects

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19011354.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


19. Lingohr P, Knoefel WT, Kleimann E, Rheinwalt KP: [Laparoscopic coincidental finding in a case of incomplete ileus: adenocarcinoma of the small intestine as first manifestation of Crohn's disease]. Zentralbl Chir; 2007 Dec;132(6):564-8
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopic coincidental finding in a case of incomplete ileus: adenocarcinoma of the small intestine as first manifestation of Crohn's disease].
  • [Transliterated title] Laparoskopischer Zufallsbefund bei inkomplettem Ileus: Adenokarzinom des Dünndarms als Erstmanifestation eines Morbus Crohn.
  • The case-study reminds of adenocarcinoma of the small intestine as a rare complication of Crohn's disease.
  • Epidemiological studies concerning small bowel carcinoma showed consumption of sugar and carbohydrates as pathogenetic factors, other conditions like ileostoma, ileumconduit, Crohn's disease and coeliac disease have been identified to some extent.
  • An adenoma-carcinoma sequence as in large intestine carcinoma has been discussed.
  • Diagnosis of early stages of adenocarcinoma of the small intestine is very difficult and thus might be impossible to differentiate from exacerbation or progressive stenosis of preexisting Crohn's disease.
  • If non-invasive diagnostic measures (ultrasound, small bowel enema, CT-scan, intestinoscopy, radiography, NMR-Sellink, capsule-endoscopy) fail to clear the situation a diagnostic laparoscopy or even laparotomy should not be delayed.
  • [MeSH-major] Adenocarcinoma / surgery. Crohn Disease / surgery. Ileal Neoplasms / surgery. Ileus / surgery. Incidental Findings. Laparoscopy
  • [MeSH-minor] Aged. Appendectomy. Cell Transformation, Neoplastic / pathology. Cholecystectomy, Laparoscopic. Cholelithiasis / diagnosis. Cholelithiasis / surgery. Diagnosis, Differential. Female. Humans. Ileum / pathology. Ileum / surgery. Intestinal Mucosa / pathology. Intestinal Mucosa / surgery. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18098087.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


20. Catassi C, Bearzi I, Holmes GK: Association of celiac disease and intestinal lymphomas and other cancers. Gastroenterology; 2005 Apr;128(4 Suppl 1):S79-86
Hazardous Substances Data Bank. GLUTEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of celiac disease and intestinal lymphomas and other cancers.
  • Celiac disease (CD) is associated with intestinal lymphoma and other forms of cancer, especially adenocarcinoma of the small intestine, of the pharynx, and of the esophagus.
  • Enteropathy-associated T-cell lymphoma (EATL) is a rare form of high-grade, T-cell non-Hodgkin lymphoma (NHL) of the upper small intestine that is specifically associated with CD.
  • EATL derives from a clonal proliferation of intraepithelial lymphocytes and is often disseminated at diagnosis.
  • [MeSH-major] Adenocarcinoma / etiology. Celiac Disease / complications. Gastrointestinal Neoplasms / etiology. Intestinal Neoplasms / etiology. Lymphoma, T-Cell / etiology

  • Genetic Alliance. consumer health - Celiac Disease.
  • MedlinePlus Health Information. consumer health - Celiac Disease.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15825131.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 8002-80-0 / Glutens
  • [Number-of-references] 40
  •  go-up   go-down


21. Varghese R, Weedon R: 'Metachronous' adenocarcinoma of the small intestine. Int J Clin Pract Suppl; 2005 Apr;(147):106-8
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 'Metachronous' adenocarcinoma of the small intestine.
  • Adenocarcinoma of the small intestine accounts for less than 1% of primary gastrointestinal malignancies (1).
  • Small intestine contains 75% of the length of the gastrointestinal tract with 90% of the surface mucosal area, and yet carcinoma is rare.
  • Symptoms of small bowel adenocarcinoma are vague and non-specific, and this region is relatively inaccessible which together contributes to their late diagnosis and poor prognosis.
  • The authors report a case of two primary adenocarcinomas of the small intestine in the same patient.
  • [MeSH-major] Adenocarcinoma / radiography. Jejunal Neoplasms / radiography. Neoplasms, Second Primary / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15875642.001).
  • [ISSN] 1368-504X
  • [Journal-full-title] International journal of clinical practice. Supplement
  • [ISO-abbreviation] Int J Clin Pract Suppl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


22. Halfdanarson TR, McWilliams RR, Donohue JH, Quevedo JF: A single-institution experience with 491 cases of small bowel adenocarcinoma. Am J Surg; 2010 Jun;199(6):797-803
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single-institution experience with 491 cases of small bowel adenocarcinoma.
  • BACKGROUND: The optimal treatment of small bowel adenocarcinoma is unknown.
  • METHODS: The records of 491 patients with small bowel adenocarcinoma diagnosis between 1970 and 2005 were reviewed for patient and tumor characteristics, treatment effects, and survival.
  • RESULTS: The median age at diagnosis was 62 years.
  • CONCLUSIONS: The prognosis of patients with small bowel adenocarcinoma is poor.
  • [MeSH-major] Adenocarcinoma / surgery. Intestinal Neoplasms / surgery. Intestine, Small

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Inc.
  • (PMID = 20609724.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Zouhairi ME, Venner A, Charabaty A, Pishvaian MJ: Small bowel adenocarcinoma. Curr Treat Options Oncol; 2008 Dec;9(4-6):388-99
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small bowel adenocarcinoma.
  • Small bowel cancers are rare, accounting for only about 6000 cases/year in the United States, approximately 25% of which are small bowel adenocarcinomas.
  • Small bowel adenocarcinomas have traditionally been considered to be highly fatal due to their nonspecific presentation at the time of diagnosis, and to the lack of responsiveness to older chemotherapy regimens.
  • Newer diagnostic techniques such as video capsule and double balloon enteroscopy may facilitate earlier diagnosis.
  • Still, there remains great need for multi-institutional, cooperative group studies to define the optimal treatment of small bowel adenocarcinoma, both in the adjuvant and advanced/metastatic setting.
  • [MeSH-major] Adenocarcinoma / epidemiology. Intestinal Neoplasms / epidemiology
  • [MeSH-minor] Age of Onset. Animals. Antimetabolites, Antineoplastic / therapeutic use. Disease Models, Animal. Female. Fluorouracil / therapeutic use. Humans. Intestine, Small / pathology. Male. Mice. Middle Aged. Neoplasm Staging. Prognosis. Risk Factors. United States / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19365735.001).
  • [ISSN] 1534-6277
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  • [Number-of-references] 40
  •  go-up   go-down


24. Zaanan A, Afchain P, Carrere N, Aparicio T: [Small bowel adenocarcinoma]. Gastroenterol Clin Biol; 2010 Aug-Sep;34(6-7):371-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Small bowel adenocarcinoma].
  • [Transliterated title] Adénocarcinome de l'intestin grêle.
  • Small bowel adenocarcinoma is a rare tumor.
  • Diagnosis is usually performed at an advanced stage because of non-specific nature of clinical manifestations.
  • New methods of radiological and endoscopic exploration of small intestine should allow earlier diagnosis.
  • A national prospective cohort study is currently evaluating the results of chemotherapy (recommended protocol: FOLFOX) as adjuvant and palliative treatment of small bowel adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / etiology. Adenocarcinoma / therapy. Intestinal Neoplasms / etiology. Intestinal Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Genetic Predisposition to Disease. Humans. Intestine, Small / pathology. Intestine, Small / surgery. Lymphatic Metastasis. Neoplasm Metastasis. Prognosis. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20537487.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  •  go-up   go-down


25. Miller AD, Kramer JA, Lin KC, Knight H, Martinot A, Mansfield KG: Small intestinal adenocarcinoma in common marmosets (Callithrix jacchus). Vet Pathol; 2010 Sep;47(5):969-76
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small intestinal adenocarcinoma in common marmosets (Callithrix jacchus).
  • Small intestinal adenocarcinomas are uncommon neoplasms that are rarely reported in nonhuman primates.
  • Herein the authors report the clinical, histologic, immunohistochemical, and molecular characteristics of small intestinal adenocarcinoma in 10 common marmosets (Callithrix jacchus).
  • Retrospective analysis of necropsy records revealed small intestinal carcinoma to be the most common neoplastic cause of morbidity and mortality in aged common marmosets.
  • Nine of 10 (90%) tumors arose within the proximal small intestine near the interface with the duodenum.
  • No Helicobacter-like bacteria were observed via silver stain, and callitrichine herpesvirus 3 was detected by polymerase chain reaction with equal frequency from neoplastic and nonneoplastic intestinal sections.
  • The tumors described in this population illustrate comparable features to human cases of small intestine carcinoma and may serve as a potential animal model for small intestinal carcinomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Microbiol. 1999 Jan;37(1):146-51 [9854080.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2693-706 [10594865.001]
  • [Cites] Am J Primatol. 2005 Jun;66(2):111-8 [15940705.001]
  • [Cites] Mod Pathol. 2006 Apr;19(4):573-80 [16501564.001]
  • [Cites] Mol Carcinog. 2006 May;45(5):349-52 [16493667.001]
  • [Cites] FEMS Microbiol Lett. 2007 Jun;271(2):239-44 [17439542.001]
  • [Cites] Infect Immun. 2008 Jun;76(6):2758-66 [18411292.001]
  • [Cites] J Exp Clin Cancer Res. 2009;28:14 [19192297.001]
  • [Cites] Cell Cycle. 2009 Aug 15;8(16):2549-56 [19597346.001]
  • [Cites] J Med Primatol. 1998 Dec;27(6):319-24 [10203013.001]
  • [Cites] Gastroenterology. 1996 Jan;110(1):102-15 [8536845.001]
  • [Cites] Lab Anim Sci. 1990 Mar;40(2):210-2 [2157108.001]
  • [Cites] J Am Vet Med Assoc. 1984 Dec 1;185(11):1377-8 [6511587.001]
  • [Cites] J Natl Cancer Inst. 1972 Feb;48(2):325-46 [4652379.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):518-26 [15274064.001]
  • [Cites] Science. 2004 Mar 5;303(5663):1483-7 [15001769.001]
  • [Cites] ANZ J Surg. 2001 Jul;71(7):428-37 [11450920.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1224-9 [11158621.001]
  • [Cites] Comp Med. 2000 Oct;50(5):540-4 [11099139.001]
  • [Cites] J Virol. 1997 May;71(5):4138-44 [9094697.001]
  • (PMID = 20460447.001).
  • [ISSN] 1544-2217
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / T32 RR007000-35; United States / NCRR NIH HHS / RR / P51 RR000168-50; United States / NCRR NIH HHS / RR / T32 RR007000; United States / NCRR NIH HHS / RR / RR00168; United States / NCRR NIH HHS / RR / P51 RR000168; United States / NCRR NIH HHS / RR / K26 RR000168; United States / NCRR NIH HHS / RR / RR07000
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ NIHMS235944; NLM/ PMC2955325
  •  go-up   go-down


26. Wu TJ, Yeh CN, Chao TC, Jan YY, Chen MF: Prognostic factors of primary small bowel adenocarcinoma: univariate and multivariate analysis. World J Surg; 2006 Mar;30(3):391-8; discussion 399

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors of primary small bowel adenocarcinoma: univariate and multivariate analysis.
  • BACKGROUND: Adenocarcinoma of the small bowel is relatively less common than malignancies of the esophagus, stomach, and colorectum.
  • In small bowel adenocarcinoma, various prognostic factors influence the disease-free status and overall survival rates.
  • MATERIALS AND METHODS: Eighty patients who were diagnosed with small bowel adenocarcinoma and treated at our institute between 1983 and 2003 were retrospectively reviewed.
  • CONCLUSIONS: Poor prognosis of small bowel adenocarcinoma may be related to a delay in the diagnosis and treatment of the disease.
  • Curative resection is the aim of surgical treatment for small bowel adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Intestinal Neoplasms / pathology. Intestine, Small

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16479330.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Chan OT, Chen ZM, Chung F, Kawachi K, Phan DC, Himmelfarb E, Lin F, Perry A, Wang HL: Lack of HER2 overexpression and amplification in small intestinal adenocarcinoma. Am J Clin Pathol; 2010 Dec;134(6):880-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of HER2 overexpression and amplification in small intestinal adenocarcinoma.
  • HER2 overexpression and amplification have been studied as a therapeutic and prognostic target in a number of human cancers, including esophageal, gastric, and colorectal adenocarcinomas.
  • However, HER2 status has not been well investigated in primary small intestinal adenocarcinoma, probably because of its rarity.
  • In this study, we conducted immunohistochemical analysis and fluorescence in situ hybridization (FISH) for HER2 on 49 primary nonampullar small intestinal adenocarcinomas.
  • These observations demonstrate that HER2 protein overexpression and gene amplification are infrequent events, if they occur at all, in small intestinal adenocarcinoma.
  • Thus, routine immunohistochemical and/or FISH testing for HER2 for potential targeted anti-HER2 therapy may not be beneficial for patients with primary small intestinal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Gene Amplification. Intestinal Neoplasms / metabolism. Intestine, Small / metabolism. Receptor, ErbB-2 / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21088150.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


28. Zhang MQ, Lin F, Hui P, Chen ZM, Ritter JH, Wang HL: Expression of mucins, SIMA, villin, and CDX2 in small-intestinal adenocarcinoma. Am J Clin Pathol; 2007 Nov;128(5):808-16
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of mucins, SIMA, villin, and CDX2 in small-intestinal adenocarcinoma.
  • Expression of gastrointestinal biomarkers MUC1, MUC2, MUC5AC, small-intestinal mucin antigen (SIMA), villin, and CDX2 has been studied in colorectal adenocarcinoma (CRC).
  • Little is known, however, about their expression in small-intestinal adenocarcinoma (SIA).
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Intestinal Neoplasms / metabolism. Intestine, Small / metabolism. Neoplasm Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17951204.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / Microfilament Proteins; 0 / Mucins; 0 / Neoplasm Proteins; 0 / gastro-intestinal mucus-associated antigens; 0 / villin
  •  go-up   go-down


29. Zhang MQ, Chen ZM, Wang HL: Immunohistochemical investigation of tumorigenic pathways in small intestinal adenocarcinoma: a comparison with colorectal adenocarcinoma. Mod Pathol; 2006 Apr;19(4):573-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical investigation of tumorigenic pathways in small intestinal adenocarcinoma: a comparison with colorectal adenocarcinoma.
  • Small intestinal adenocarcinoma is an uncommon neoplasm morphologically similar to or indistinguishable from colorectal adenocarcinoma.
  • Although much has been learned about genetic pathways critical to colorectal tumorigenesis, little is known about molecular alterations involved in the development of small intestinal adenocarcinoma.
  • In this study, we immunohistochemically compared non-ampullary small intestinal adenocarcinomas with sporadic colorectal adenocarcinomas for the expression of several proteins known to serve pivotal roles in colorectal tumorigenesis.
  • The results show that complete loss of adenomatous polyposis coli immunoreactivity, presumably resulting from its gene mutations, was observed in eight of 26 (31%) small intestinal adenocarcinomas and 36 of 51 (71%) colorectal adenocarcinomas (P = 0.0008).
  • Nuclear localization of beta-catenin, an indirect evidence of deregulated Wnt signaling pathway, was observed in 5 (19%) small intestinal adenocarcinomas and 36 (71%) colorectal adenocarcinomas (P<0.0001).
  • Total lack of nuclear staining for one or more of the DNA mismatch repair enzymes occurred in a similar low frequency in both small intestinal and colorectal adenocarcinomas, seen in two of 25 (8%) and 10 of 47 (21%) cases, respectively (P = 0.1958).
  • The frequencies of aberrant p53 and RB expression were also similar between small intestinal and colorectal adenocarcinomas.
  • These observations indicate that defects in the Wnt and microsatellite instability pathways occur in over 90% of colorectal adenocarcinomas, but in only 40% of small intestinal adenocarcinomas.
  • Small intestinal tumorigenesis appears to follow a distinct, yet unidentified, molecular pathway(s) from its colorectal counterpart despite their morphologic similarity.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology. Intestinal Neoplasms / pathology. Intestine, Small / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16501564.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Adenomatous Polyposis Coli Protein; 0 / Carrier Proteins; 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein; 0 / MLH1 protein, human; 0 / MLH2 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Retinoblastoma Protein; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 0 / beta Catenin
  •  go-up   go-down


30. Terado Y, Kurata A, Ishida T, Imamura T, Sakamoto A: Adenocarcinoma of small intestinal type in retroperitoneal mature teratoma. Pathol Int; 2010 Oct;60(10):701-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of small intestinal type in retroperitoneal mature teratoma.
  • We report a case of small intestinal type adenocarcinoma arising in retroperitoneal mature cystic teratoma in a young male.
  • Adenocarcinoma without stromal invasion was observed adjacent to the small intestinal mucosa.
  • Immunohistochemistry of the adenocarcinoma tissue revealed p53 overexpression and high Ki-67 labeling index as well as positive staining for CD10, cytokeratin 7, and cytokeratin 20.
  • Therefore, the diagnosis of small intestinal adenocarcinoma was made.
  • To our knowledge, this is the first case of small intestinal adenocarcinoma arising in retroperitoneal mature cystic teratoma.
  • A unique feature of this case is that malignant transformation in retroperitoneal mature teratoma arose even in the fully developed intestine.
  • [MeSH-major] Adenocarcinoma / pathology. Neoplasms, Multiple Primary / pathology. Retroperitoneal Neoplasms / pathology. Teratoma / pathology

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Pathology International © 2010 Japanese Society of Pathology and Blackwell Publishing Asia Pty Ltd.
  • [ErratumIn] Pathol Int. 2010 Dec;60(12):798
  • (PMID = 20846270.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


31. Kodaira C, Osawa S, Mochizuki C, Sato Y, Nishino M, Yamada T, Takayanagi Y, Takagaki K, Sugimoto K, Kanaoka S, Furuta T, Ikuma M: A case of small bowel adenocarcinoma in a patient with Crohn's disease detected by PET/CT and double-balloon enteroscopy. World J Gastroenterol; 2009 Apr 14;15(14):1774-8
MedlinePlus Health Information. consumer health - Crohn's Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of small bowel adenocarcinoma in a patient with Crohn's disease detected by PET/CT and double-balloon enteroscopy.
  • Small bowel adenocarcinoma (SBA) in patients with Crohn's disease (CD) is quite rare, difficult to diagnose without surgery, and has a poor prognosis.
  • PET/CT detected an accumulation spot in the small bowel.
  • An endoscopic forceps biopsy specimen showed poorly differentiated adenocarcinoma.
  • There were some longitudinal ulcer scars near the tumor, and the chronic inflammation in the small bowel appeared to be associated with the cancer development.
  • Since early diagnosis is extremely difficult in these cases, novel techniques, such as PET/CT and DBE, may be expected to help in making a preoperative diagnosis of the development of SBA in CD.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / etiology. Crohn Disease / complications. Endoscopy, Gastrointestinal / methods. Intestinal Neoplasms / diagnosis. Intestinal Neoplasms / etiology. Intestine, Small / pathology

  • Genetic Alliance. consumer health - Crohn Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 2001 Apr;48(4):526-35 [11247898.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):854-62 [11241255.001]
  • [Cites] Scand J Gastroenterol. 2001 Jun;36(6):641-6 [11424324.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2002 Jul;14(7):805-10 [12169995.001]
  • [Cites] Am J Gastroenterol. 2003 Aug;98(8):1682-7 [12907319.001]
  • [Cites] JAMA. 2003 Dec 24;290(24):3199-206 [14693872.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Feb 1;19(3):287-93 [14984375.001]
  • [Cites] Inflamm Bowel Dis. 2004 Jan;10(1):32-5 [15058524.001]
  • [Cites] Dis Colon Rectum. 2004 May;47(5):778-81 [15037927.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2004 Aug;16(8):767-73 [15256978.001]
  • [Cites] Am J Surg. 1980 Sep;140(3):396-9 [7425215.001]
  • [Cites] Am J Gastroenterol. 1983 Jan;78(1):44-6 [6849315.001]
  • [Cites] Cancer. 1983 Mar 1;51(5):878-81 [6821853.001]
  • [Cites] Dig Dis Sci. 1992 Aug;37(8):1179-84 [1499440.001]
  • [Cites] Gastroenterology. 1993 Dec;105(6):1716-23 [8253348.001]
  • [Cites] Gastroenterology. 1994 Dec;107(6):1675-9 [7958678.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1996 Dec;8(12):1179-83 [8980937.001]
  • [Cites] Gastroenterol Clin North Am. 1999 Jun;28(2):459-77, x [10372277.001]
  • [Cites] Int J Cancer. 1999 Jul 19;82(2):171-4 [10389747.001]
  • [Cites] Am J Gastroenterol. 1999 Jul;94(7):1746-50 [10406230.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):963-9 [10435567.001]
  • [Cites] Surgery. 1956 Feb;39(2):347-51 [13298987.001]
  • [Cites] World J Gastroenterol. 2006 Feb 28;12(8):1317-20 [16534894.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Apr 15;23(8):1097-104 [16611269.001]
  • [Cites] Am J Gastroenterol. 2006 Jul;101(7):1484-9 [16863550.001]
  • [Cites] Am J Gastroenterol. 2006 Oct;101(10):2218-22 [16848804.001]
  • [Cites] J Chemother. 2006 Oct;18(5):545-8 [17127233.001]
  • [Cites] JAMA. 2006 Dec 6;296(21):2590-600 [17148724.001]
  • [Cites] Dis Colon Rectum. 2007 Jun;50(6):839-55 [17308939.001]
  • [Cites] J Nucl Med. 2007 Jul;48(7):1053-9 [17574978.001]
  • [Cites] World J Gastroenterol. 2007 Jun 28;13(24):3279-87 [17659666.001]
  • [Cites] World J Gastroenterol. 2007 Dec 14;13(46):6140-9 [18069752.001]
  • [Cites] Am Surg. 2007 Nov;73(11):1181-7 [18092659.001]
  • [Cites] World J Gastroenterol. 2008 Jan 21;14(3):378-89 [18200660.001]
  • [Cites] Am J Gastroenterol. 2008 Jul;103(7):1730-6 [18564124.001]
  • [Cites] Gastroenterology. 2001 Mar;120(4):820-6 [11231935.001]
  • (PMID = 19360924.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2668786
  •  go-up   go-down


32. Piton G, Cosnes J, Monnet E, Beaugerie L, Seksik P, Savoye G, Cadiot G, Flourie B, Capelle P, Marteau P, Lemann M, Colombel JF, Khouri E, Bonaz B, Carbonnel F: Risk factors associated with small bowel adenocarcinoma in Crohn's disease: a case-control study. Am J Gastroenterol; 2008 Jul;103(7):1730-6
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors associated with small bowel adenocarcinoma in Crohn's disease: a case-control study.
  • BACKGROUND AND AIMS: It is well established that Crohn's disease (CD) is associated with an increased risk of small bowel adenocarcinoma (SBA).
  • METHODS: In 11 French centers affiliated with the GETAID (Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif), we identified 29 patients with CD and SBA.
  • RESULTS: In univariate analysis, the cases had had significantly less small bowel resection and received prolonged treatment with salicylates (more than 2 yr), less often than the controls (odds ratio, OR [95% confidence interval, CI] 0.07 [0.01-0.32] and 0.29 [0.10-0.82], respectively).
  • CONCLUSION: This study suggests that small bowel resection and prolonged salicylates use may protect against SBA in CD patients.
  • [MeSH-major] Adenocarcinoma / etiology. Crohn Disease / complications. Intestinal Neoplasms / etiology. Intestine, Small

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Inflamm Bowel Dis. 2009 Sep;15(9):1434-5 [19202570.001]
  • (PMID = 18564124.001).
  • [ISSN] 1572-0241
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Salicylates
  •  go-up   go-down


33. Thomsen Lønborg J, Vilmar A, Mård D, Astrup Jensen S, Sørensen JB: Prognosis of small bowel adenocarcinoma treated with Mayo or Xelox regimen: a matched case-control study from a database of 581 patients with colorectal cancer. Oncol Rep; 2007 Oct;18(4):1023-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of small bowel adenocarcinoma treated with Mayo or Xelox regimen: a matched case-control study from a database of 581 patients with colorectal cancer.
  • The purpose of this study was to compare the effects of chemotherapy on the prognosis for patients with adenocarcinoma of the small bowel (SBC) and colorectal cancer (CRC).
  • However, reliable conclusions cannot be drawn from a small patient population, and multicentre studies are needed.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy. Intestine, Small / drug effects

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17786369.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Organoplatinum Compounds; 0W860991D6 / Deoxycytidine; U3P01618RT / Fluorouracil; XELOX
  •  go-up   go-down


34. Mehta MV, Porecha MM, Mehta PJ: Small intestinal adenocarcinoma in Peutz-Jeghers syndrome. Indian J Gastroenterol; 2006 Jan-Feb;25(1):38-9
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small intestinal adenocarcinoma in Peutz-Jeghers syndrome.
  • Peutz-Jeghers syndrome (PJS) is characterized by intestinal hamartomatous polyposis (usually affecting the jejunum) and mucocutaneous melanin spots.
  • We report a 25-year-old man with PJS who developed small intestinal adenocarcinoma and presented with small bowel obstruction due to jejuno-ileal intussusception.
  • [MeSH-major] Adenocarcinoma / etiology. Jejunal Neoplasms / etiology. Peutz-Jeghers Syndrome / complications

  • Genetic Alliance. consumer health - Peutz Jeghers syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16567896.001).
  • [ISSN] 0254-8860
  • [Journal-full-title] Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
  • [ISO-abbreviation] Indian J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


35. Husain S, Thompson D, Thomas L, Donaldson B, Sabbagh R: Adnexal mass: an unusual presentation of small-bowel adenocarcinoma. J Natl Med Assoc; 2006 May;98(5):799-802
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adnexal mass: an unusual presentation of small-bowel adenocarcinoma.
  • Malignancy of the small bowel presents unique diagnostic and therapeutic challenges resulting in a delayed diagnosis in many cases.
  • Small-bowel tumors respond poorly to most forms of treatment.
  • Metastatic lesions to the ovaries comprise a small percentage of all ovarian malignant neoplasms.
  • Ovarian metastases from primary small-bowel tumors are often difficult to differentiate from primary ovarian tumors.
  • Only few reports have described ovarian metastases from small-bowel sources.
  • A high index of suspicion can lead to an earlier diagnosis and can have an impact on the therapeutic options as well as the survival of the patients.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adnexal Diseases / diagnosis. Intestinal Neoplasms / diagnosis. Intestine, Small / pathology
  • [MeSH-minor] Abdominal Pain. Diagnosis, Differential. Female. Humans. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2000 Aug;78(2):255-8 [10926813.001]
  • [Cites] Gynecol Oncol. 2004 Apr;93(1):87-91 [15047218.001]
  • [Cites] Cancer. 1983 Mar 1;51(5):878-81 [6821853.001]
  • [Cites] Semin Diagn Pathol. 1991 Aug;8(3):149-62 [1925122.001]
  • [Cites] AJR Am J Roentgenol. 1999 Feb;172(2):373-8 [9930786.001]
  • [Cites] Langenbecks Arch Surg. 1999 Apr;384(2):176-80 [10328171.001]
  • [Cites] Am J Surg Pathol. 1987 Feb;11(2):114-21 [3812871.001]
  • (PMID = 16749659.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2569296
  •  go-up   go-down


36. Delaunoit T, Neczyporenko F, Limburg PJ, Erlichman C: Pathogenesis and risk factors of small bowel adenocarcinoma: a colorectal cancer sibling? Am J Gastroenterol; 2005 Mar;100(3):703-10
Genetic Alliance. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathogenesis and risk factors of small bowel adenocarcinoma: a colorectal cancer sibling?
  • Small bowel adenocarcinoma (SBA) is a very rare entity accounting for one-fourth of the small intestine neoplasms.
  • It appears that SBA shares several genetic characteristics with large bowel tumors, but also has unique features.
  • [MeSH-major] Adenocarcinoma / etiology. Intestinal Neoplasms / etiology. Intestine, Small

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15743371.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 101
  •  go-up   go-down


37. Bergmann F, Singh S, Michel S, Kahlert C, Schirmacher P, Helmke B, Von Knebel Doeberitz M, Kloor M, Bläker H: Small bowel adenocarcinomas in celiac disease follow the CIM-MSI pathway. Oncol Rep; 2010 Dec;24(6):1535-9
MedlinePlus Health Information. consumer health - Celiac Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small bowel adenocarcinomas in celiac disease follow the CIM-MSI pathway.
  • Celiac disease (CD) is an inflammatory disorder associated with an increased risk of small bowel adenocarcinoma.
  • We hypothesized that CIM may link CD to small bowel carcinogenesis.
  • We determined microsatellite instability (MSI), CIM, and expression of MLH1 and MGMT in 3 CD-associated small bowel carcinomas and corresponding non-neoplastic mucosa.
  • The results were compared to those of small bowel mucosa from CD patients without carcinoma and 20 small bowel carcinomas from a non-CD origin.
  • In conclusion, our data reveal that the high-level CIM/MSI pathway is typical of CD-associated small bowel carcinomas and indicate that aberrant CpG island methylation links CD and carcinogenesis.
  • The data further suggest that CD should be considered in patients with small bowel adenocarcinoma, particularly when the tumors display MSI.
  • [MeSH-major] Adenocarcinoma / genetics. Celiac Disease / genetics. CpG Islands. DNA Methylation. Intestinal Neoplasms / genetics. Microsatellite Instability
  • [MeSH-minor] Adaptor Proteins, Signal Transducing / genetics. Adult. Aged. Aged, 80 and over. Cohort Studies. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Humans. Intestinal Mucosa / metabolism. Intestinal Mucosa / pathology. Intestine, Small / metabolism. Intestine, Small / pathology. Male. Middle Aged. Nuclear Proteins / genetics. Signal Transduction / genetics. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Celiac Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21042749.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / MLH1 protein, human; 0 / Nuclear Proteins; 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


38. Trikudanathan G, Dasanu CA: Evolving pharmacotherapeutic strategies for small bowel adenocarcinoma. Expert Opin Pharmacother; 2010 Jul;11(10):1695-704
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evolving pharmacotherapeutic strategies for small bowel adenocarcinoma.
  • IMPORTANCE OF THE FIELD: Owing to nonspecific signs and symptoms, the majority of patients with small bowel adenocarcinoma (SBA) present with advanced-stage disease.
  • [MeSH-major] Adenocarcinoma / drug therapy. Intestinal Neoplasms / drug therapy. Intestine, Small / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20446863.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 7673326042 / irinotecan; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 48
  •  go-up   go-down


39. Verma D, Stroehlein JR: Adenocarcinoma of the small bowel: a 60-yr perspective derived from M. D. Anderson Cancer Center Tumor Registry. Am J Gastroenterol; 2006 Jul;101(7):1647-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the small bowel: a 60-yr perspective derived from M. D. Anderson Cancer Center Tumor Registry.
  • OBJECTIVES: To analyze subsite distribution of small bowel adenocarcinoma (SBA) over a 60-yr interval and to determine the impact of age, gender, and ethnicity on SBA cross-referenced for selected variables including anatomic distribution.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Intestinal Neoplasms / epidemiology. Intestinal Neoplasms / pathology. Intestine, Small

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16863573.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Palascak-Juif V, Bouvier AM, Cosnes J, Flourié B, Bouché O, Cadiot G, Lémann M, Bonaz B, Denet C, Marteau P, Gambiez L, Beaugerie L, Faivre J, Carbonnel F: Small bowel adenocarcinoma in patients with Crohn's disease compared with small bowel adenocarcinoma de novo. Inflamm Bowel Dis; 2005 Sep;11(9):828-32
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small bowel adenocarcinoma in patients with Crohn's disease compared with small bowel adenocarcinoma de novo.
  • BACKGROUND: Data concerning small bowel adenocarcinoma (SBA) in Crohn's disease (CD) come from case reports and small retrospective series.
  • The aim of this study was to further describe SBA in patients with CD and compare it with SBA de novo.
  • METHODS: Twenty patients with CD with SBA recruited in French university hospitals were studied and compared with 40 patients with SBA de novo recruited from a population-based registry.
  • SBA occurred after a median time of 15 years of CD and was located within the inflamed areas of the ileum (n=19) or jejunum (n=1), whereas in patients with SBA de novo, it was distributed all along the small intestine.
  • Median age at diagnosis of SBA was 47 years (range, 33-72 yr) in patients with CD and 68 years (range, 41-95 yr) in those with SBA de novo.
  • Diagnosis was made preoperatively in 1/20 patients with CD and 22/40 patients with SBA de novo.
  • Signet ring cells were found in 35% of patients with CD but not in patients with SBA de novo.
  • CONCLUSIONS: SBA in CD is different from SBA de novo.
  • [MeSH-major] Adenocarcinoma / pathology. Crohn Disease / complications. Ileal Neoplasms / pathology

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16116317.001).
  • [ISSN] 1078-0998
  • [Journal-full-title] Inflammatory bowel diseases
  • [ISO-abbreviation] Inflamm. Bowel Dis.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Kronberger IE, Graziadei IW, Vogel W: Small bowel adenocarcinoma in Crohn's disease: a case report and review of literature. World J Gastroenterol; 2006 Feb 28;12(8):1317-20
Hazardous Substances Data Bank. MESALAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small bowel adenocarcinoma in Crohn's disease: a case report and review of literature.
  • Small bowel adenocarcinomas are remarkable for their rarity, difficult diagnosis and poor prognosis.
  • Here we report an unusual case of a 33-year-old patient in whom infiltrative adenocarcinoma of the small bowel was diagnosed after a 10-year history of Crohn's disease.
  • In most previously reported cases, detection of Crohn's disease was subsequent to that of carcinoma of the small bowel or the patients involved had an even longer history of the disease.
  • Our literature review suggests that the risk of small bowel adenocarcinoma is higher in patients with Crohn's disease than in the overall population.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Crohn Disease / complications. Crohn Disease / diagnosis. Ileal Neoplasms / complications. Ileal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1985 May;28(5):361-6 [3158499.001]
  • [Cites] Gut. 1982 Mar;23(3):188-93 [7040175.001]
  • [Cites] Surg Gynecol Obstet. 1991 Nov;173(5):343-9 [1948581.001]
  • [Cites] Dig Dis Sci. 1992 Aug;37(8):1179-84 [1499440.001]
  • [Cites] Gastroenterology. 1992 Nov;103(5):1444-51 [1358741.001]
  • [Cites] Dis Colon Rectum. 1993 Jul;36(7):654-61 [8348849.001]
  • [Cites] Gastroenterology. 1993 Dec;105(6):1716-23 [8253348.001]
  • [Cites] Lancet. 1994 May 21;343(8908):1249-52 [7910274.001]
  • [Cites] Dis Colon Rectum. 1996 Nov;39(11):1315-21 [8918446.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1996 Dec;8(12):1179-83 [8980937.001]
  • [Cites] Gastroenterology. 1997 Jul;113(1):127-35 [9207270.001]
  • [Cites] J Comput Assist Tomogr. 1997 Nov-Dec;21(6):986-91 [9386295.001]
  • [Cites] Am J Surg Pathol. 1998 Mar;22(3):275-84 [9500769.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1998 May;10(5):431-2 [9619392.001]
  • [Cites] Lab Invest. 1998 Sep;78(9):1155-67 [9759659.001]
  • [Cites] Am J Surg Pathol. 1999 Jun;23(6):651-5 [10366146.001]
  • [Cites] Gastroenterol Clin North Am. 1999 Jun;28(2):459-77, x [10372277.001]
  • [Cites] J Gastroenterol Hepatol. 1999 Nov;14(11):1132-4 [10574144.001]
  • [Cites] Clin Imaging. 1999 Sep-Oct;23(5):298-301 [10665347.001]
  • [Cites] BMJ. 2000 Sep 30;321(7264):805-8 [11009523.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):854-62 [11241255.001]
  • [Cites] Gut. 2001 Apr;48(4):526-35 [11247898.001]
  • [Cites] Harefuah. 2001 Apr;140(4):289-93, 368 [11303390.001]
  • [Cites] Scand J Gastroenterol. 2001 Jun;36(6):641-6 [11424324.001]
  • [Cites] Aliment Pharmacol Ther. 2002 Jul;16(7):1225-32 [12144571.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2002 Jul;14(7):805-10 [12169995.001]
  • [Cites] Scand J Gastroenterol Suppl. 2002;(236):48-53 [12408504.001]
  • [Cites] Dis Colon Rectum. 2002 Nov;45(11):1496-502 [12432298.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2002 Jul;12(3):495-523 [12486941.001]
  • [Cites] Histopathology. 2003 Apr;42(4):404-5 [12653953.001]
  • [Cites] Lancet Infect Dis. 2003 Aug;3(8):507-14 [12901893.001]
  • [Cites] Am J Gastroenterol. 2003 Aug;98(8):1682-7 [12907319.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:1-5 [12950413.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:10-4 [12950415.001]
  • [Cites] Australas Radiol. 2003 Dec;47(4):450-2 [14641202.001]
  • [Cites] Endoscopy. 2003 Dec;35(12):1009-14 [14648412.001]
  • [Cites] J Comput Assist Tomogr. 2004 Jan-Feb;28(1):106-16 [14716243.001]
  • [Cites] Scand J Gastroenterol Suppl. 2003;(239):63-8 [14743885.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Feb 1;19(3):287-93 [14984375.001]
  • [Cites] Am J Gastroenterol. 2004 Feb;99(2):299-305 [15046221.001]
  • [Cites] Inflamm Bowel Dis. 2004 Jan;10(1):32-5 [15058524.001]
  • [Cites] Cochrane Database Syst Rev. 2004;(2):CD000279 [15106148.001]
  • [Cites] Dis Colon Rectum. 2004 May;47(5):778-81 [15037927.001]
  • [Cites] Radiographics. 2004 May-Jun;24(3):689-702 [15143222.001]
  • [Cites] Inflamm Bowel Dis. 2004 Feb;10 Suppl 1:S32-4 [15168828.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Jun;2(6):491-7 [15181618.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2004 Aug;16(8):767-73 [15256978.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):518-26 [15274064.001]
  • [Cites] World J Gastroenterol. 2004 Sep 1;10(17):2585-7 [15300912.001]
  • [Cites] Gastroenterol Nurs. 2004 Jul-Aug;27(4):170-5 [15326402.001]
  • [Cites] Rev Gastroenterol Disord. 2004 Summer;4(3):104-17 [15359211.001]
  • [Cites] Z Gastroenterol. 2004 Oct;42(10):1256-63 [15508068.001]
  • [Cites] Gut. 1973 Feb;14(2):120-4 [4696534.001]
  • [Cites] Am J Dig Dis. 1973 Dec;18(12):1095-8 [4761532.001]
  • [Cites] Am J Med. 1975 Aug;59(2):262-8 [1155482.001]
  • [Cites] Cancer. 1976 Jun;37(6):2948-59 [949714.001]
  • [Cites] Clin Oncol. 1977 Dec;3(4):377-81 [598065.001]
  • [Cites] Gastroenterology. 1987 Dec;93(6):1307-14 [2824276.001]
  • (PMID = 16534894.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 4Q81I59GXC / Mesalamine; MRK240IY2L / Azathioprine
  • [Number-of-references] 60
  • [Other-IDs] NLM/ PMC4124452
  •  go-up   go-down


42. Bruckner HW, Hrehorovich VR, Sawhney HS, Meeus SI, Coopeman AM: Chemotherapeutic management of small bowel adenocarcinoma associated with Crohn's disease. J Chemother; 2006 Oct;18(5):545-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapeutic management of small bowel adenocarcinoma associated with Crohn's disease.
  • Four patients with metastatic primary small bowel adenocarcinoma associated with Crohn's disease were successfully treated with low dose combination chemotherapy consisting of 5-fluorouracil, leucovorin and irinotecan with or without gemcitabine.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Crohn Disease / complications. Duodenal Neoplasms / drug therapy. Ileal Neoplasms / drug therapy. Jejunal Neoplasms / drug therapy
  • [MeSH-minor] Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Female. Humans. Intestine, Small / pathology. Leucovorin / administration & dosage. Male. Remission Induction. Survival Analysis

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17127233.001).
  • [ISSN] 1120-009X
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


43. Cardona DM, Zhang X, Liu C: Loss of carbamoyl phosphate synthetase I in small-intestinal adenocarcinoma. Am J Clin Pathol; 2009 Dec;132(6):877-82
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of carbamoyl phosphate synthetase I in small-intestinal adenocarcinoma.
  • Carbamoyl phosphate synthetase I (CPS1), normally found in hepatocytes and small-intestine (SI) enterocytes, is the antigen of Hep Par 1 antibody.
  • Expression of CPS1 in invasive SI adenocarcinoma seems to be lost.
  • We retrospectively collected 36 total specimens, which included 31 SI adenomas and 21 adenocarcinomas.
  • Of the 21 invasive adenocarcinomas, 15 lost antigen expression (71%).
  • [MeSH-major] Adenocarcinoma / enzymology. Carbamoyl-Phosphate Synthase (Ammonia) / metabolism. Duodenal Neoplasms / enzymology. Duodenum / enzymology
  • [MeSH-minor] Adenoma / enzymology. Adenoma / pathology. Biomarkers, Tumor / metabolism. Duodenitis / enzymology. Duodenitis / pathology. Humans. Immunohistochemistry. Intestinal Mucosa / enzymology. Intestinal Mucosa / pathology. Neoplasm Invasiveness. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19926579.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 6.3.4.16 / Carbamoyl-Phosphate Synthase (Ammonia)
  •  go-up   go-down


44. Sumrall A, Soni N: Dermatofibrosarcoma protuberans and small bowel adenocarcinoma: coincidental occurrence or genetic association? Int J Gastrointest Cancer; 2006;37(4):146-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermatofibrosarcoma protuberans and small bowel adenocarcinoma: coincidental occurrence or genetic association?
  • After surgical excision and radiotherapy of dermatofibrosarcoma protuberans, the patient developed small bowel adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Dermatofibrosarcoma / pathology. Intestinal Neoplasms / pathology. Neoplasms, Second Primary / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Intestine, Small / pathology. Intestine, Small / radiography. Male. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - Dermatofibrosarcoma Protuberans.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18175227.001).
  • [ISSN] 1537-3649
  • [Journal-full-title] International journal of gastrointestinal cancer
  • [ISO-abbreviation] Int J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


45. Sasaki Y, Natsuizaka M, Takano M, Suzuki M, Tsuyuguchi M, Nagasako T, Kawamura N, Kudo M, Tsuda I, Meguro J: [A case of primary adenocarcinoma of small intestine with multiple liver metastases successfully treated with mFOLFOX6]. Gan To Kagaku Ryoho; 2009 Nov;36(11):1927-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary adenocarcinoma of small intestine with multiple liver metastases successfully treated with mFOLFOX6].
  • Biopsy of the tumor was performed and pathological examination revealed adenocarcinoma.
  • Histopathological examination revealed moderately-differentiated adenocarcinoma of Bauhin's valve and the terminal ileum, and no adenocarcinoma was found in the cecum and ascending colon.
  • He was diagnosed with primary adenocarcinoma of the ileum with multiple liver metastases.
  • Effectiveness of mFOLFOX6 for primary adenocarcinoma of small intestine is suggested.
  • [MeSH-major] Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ileal Neoplasms / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19920403.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


46. Jacks SP, Hundley JC, Shen P, Russell GB, Levine EA: Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis from small bowel adenocarcinoma. J Surg Oncol; 2005 Aug 1;91(2):112-7; discussion 118-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis from small bowel adenocarcinoma.
  • Small bowel adenocarcinoma is a rare etiology for PC.
  • METHODS: From a prospective database of IPHC patients, six patients diagnosed with PC from adenocarcinoma of the small bowel were identified.
  • Median survival after diagnosis of small bowel adenocarcinoma was 54 months, while median survival after CS and IPHC for PC was 30.1 months.
  • CONCLUSIONS: Small bowel adenocarcinoma with PC remains an unusual therapeutic challenge.
  • [MeSH-major] Adenocarcinoma / drug therapy. Hyperthermia, Induced. Ileal Neoplasms / drug therapy. Jejunal Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16028284.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


47. Stratopoulos C, Papakonstantinou A, Anagnostopoulos G, Terzis I, Tzimas G, Gourgiotis S, Vamvouka C, Hadjiyannakis E: Intestinal neurofibromatosis and small-bowel adenocarcinoma: a single case study. Eur J Cancer Care (Engl); 2009 Sep;18(5):466-9
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal neurofibromatosis and small-bowel adenocarcinoma: a single case study.
  • However, the coexistence of neurofibromatosis with small-bowel adenocarcinoma is exceedingly rare.
  • We present an uncommon case of neurofibromatosis type 1, involving the small bowel in a 73-year-old man, who was admitted to our department with signs of acute abdomen.
  • These nodules obstructed ileal lumen, while the intestine wall was perforated in one point.
  • Histology revealed neurofibromatosis type 1 with malignant transformation to small-bowel adenocarcinoma.
  • We suggest that adenocarcinoma of small bowel should be considered in the evaluation of acute abdominal pain in neurofibromatosis patients.
  • [MeSH-major] Adenocarcinoma / pathology. Ileal Neoplasms / pathology. Intestine, Small / pathology. Neoplasms, Multiple Primary / pathology. Neurofibromatosis 1 / pathology
  • [MeSH-minor] Abdomen, Acute / etiology. Aged. Follow-Up Studies. Humans. Intestinal Obstruction / etiology. Intestinal Obstruction / pathology. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19473375.001).
  • [ISSN] 1365-2354
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


48. Speranza G, Doroshow JH, Kummar S: Adenocarcinoma of the small bowel: changes in the landscape? Curr Opin Oncol; 2010 Jul;22(4):387-93

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the small bowel: changes in the landscape?
  • PURPOSE OF REVIEW: Small bowel adenocarcinoma (SBA) is a rare cancer with a poor prognosis and little information to guide its management.
  • RECENT FINDINGS: Recent advances in less invasive imaging tools may permit earlier and increased diagnosis of SBA.
  • SUMMARY: The rarity of the disease and difficulty in diagnosis contribute to the lack of prospective trials evaluating therapies for SBA.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Intestine, Small / drug effects. Intestine, Small / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20485170.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 2S9ZZM9Q9V / Bevacizumab; B76N6SBZ8R / gemcitabine
  • [Number-of-references] 43
  •  go-up   go-down


49. Overman MJ, Hu CY, Wolff RA, Chang GJ: Prognostic value of lymph node evaluation in small bowel adenocarcinoma: analysis of the surveillance, epidemiology, and end results database. Cancer; 2010 Dec 1;116(23):5374-82
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of lymph node evaluation in small bowel adenocarcinoma: analysis of the surveillance, epidemiology, and end results database.
  • BACKGROUND: The presence of distant metastases and the completeness of resection are important prognostic factors in patients with small bowel adenocarcinoma (SBA); however, the influence of lymph node metastasis on patient outcome has not been well characterized.
  • [MeSH-major] Adenocarcinoma / pathology. Intestinal Neoplasms / pathology. Intestine, Small. Lymph Nodes / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Cancer Society.
  • (PMID = 20715162.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


50. Feldstein RC, Sood S, Katz S: Small bowel adenocarcinoma in Crohn's disease. Inflamm Bowel Dis; 2008 Aug;14(8):1154-7
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small bowel adenocarcinoma in Crohn's disease.
  • Small bowel neoplastic disease is a rare but dreaded occurrence in Crohn's disease (CD) and the diagnosis is often disguised by nonspecific and varied presenting symptoms mimicking active or obstructive CD.
  • As such, the diagnosis is all too often delayed, typically detected at a late stage, and with a poor prognosis.
  • CD has become a well-recognized risk factor for the development of small bowel adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / epidemiology. Crohn Disease / complications. Ileal Neoplasms / epidemiology. Jejunal Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18275076.001).
  • [ISSN] 1536-4844
  • [Journal-full-title] Inflammatory bowel diseases
  • [ISO-abbreviation] Inflamm. Bowel Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 37
  •  go-up   go-down


51. Czaykowski P, Hui D: Chemotherapy in small bowel adenocarcinoma: 10-year experience of the British Columbia Cancer Agency. Clin Oncol (R Coll Radiol); 2007 Mar;19(2):143-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy in small bowel adenocarcinoma: 10-year experience of the British Columbia Cancer Agency.
  • AIMS: Small bowel adenocarcinoma (SBA) is a rare, frequently lethal, malignancy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Intestinal Neoplasms / drug therapy. Intestine, Small / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17355111.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


52. Mac MT, Chung F, Lin F, Hui P, Balzer BL, Wang HL: Expression of hepatocyte antigen in small intestinal epithelium and adenocarcinoma. Am J Clin Pathol; 2009 Jul;132(1):80-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of hepatocyte antigen in small intestinal epithelium and adenocarcinoma.
  • Hepatocyte antigen expression has also been detected in nonneoplastic small intestinal epithelium, but expression in small intestinal adenocarcinoma has not been well investigated.
  • We immunohistochemically examined 39 nonampullary small intestinal adenocarcinomas for hepatocyte antigen expression; 34 cases contained normal-appearing nonneoplastic small intestinal mucosa on the same tissue sections.
  • Only 9 small intestinal adenocarcinomas (23%) showed focal positive cytoplasmic staining.
  • In 31 colorectal adenocarcinomas, 3 (10%) showed positive staining for Hep Par 1 (1 diffuse, 2 focal), a frequency not different from that for small intestinal adenocarcinomas (P = .2467).
  • Hepatocyte antigen immunoreactivity is selectively expressed in nonneoplastic small intestinal enterocytes but not in colonocytes, suggesting a potential physiologic role in intestinal biology.
  • Whether the loss of antigen expression in a large number of small intestinal adenocarcinomas serves a role in small intestinal tumorigenesis remains to be investigated.
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens / metabolism. Intestinal Mucosa / metabolism. Intestinal Neoplasms / metabolism. Intestine, Small / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19864237.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 0 / Biomarkers, Tumor
  •  go-up   go-down


53. Fishman PN, Pond GR, Moore MJ, Oza A, Burkes RL, Siu LL, Feld R, Gallinger S, Greig P, Knox JJ: Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases. Am J Clin Oncol; 2006 Jun;29(3):225-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases.
  • BACKGROUND: Small bowel adenocarcinoma is a rare cancer that has generally been considered resistant to chemotherapy, although little has been published on the role of chemotherapy.
  • A retrospective analysis was conducted of patients with advanced small bowel adenocarcinoma to explore chemotherapy use, and gain knowledge for ongoing management and future clinical trials.
  • PATIENTS AND METHODS: All patients with advanced adenocarcinoma of the small bowel treated at Princess Margaret Hospital (PMH) between 1986 and 2004 were identified through the cancer registry.
  • CONCLUSION: Chemotherapy appears to have activity in adenocarcinoma of the small bowel.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Intestinal Neoplasms / drug therapy. Intestinal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16755174.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Diosdado B, Buffart TE, Watkins R, Carvalho B, Ylstra B, Tijssen M, Bolijn AS, Lewis F, Maude K, Verbeke C, Nagtegaal ID, Grabsch H, Mulder CJ, Quirke P, Howdle P, Meijer GA: High-resolution array comparative genomic hybridization in sporadic and celiac disease-related small bowel adenocarcinomas. Clin Cancer Res; 2010 Mar 1;16(5):1391-401
MedlinePlus Health Information. consumer health - Celiac Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution array comparative genomic hybridization in sporadic and celiac disease-related small bowel adenocarcinomas.
  • PURPOSE: The molecular pathogenesis of small intestinal adenocarcinomas is not well understood.
  • Understanding the molecular characteristics of small bowel adenocarcinoma may lead to more effective patient treatment.
  • EXPERIMENTAL DESIGN: Forty-eight small bowel adenocarcinomas (33 non-celiac disease related and 15 celiac disease related) were characterized for chromosomal aberrations by high-resolution array comparative hybridization, microsatellite instability, and APC promoter methylation and mutation status.
  • Furthermore, molecular alterations were compared between celiac disease-related and non-celiac disease-related small bowel adenocarcinomas.
  • RESULTS: DNA copy number changes were observed in 77% small bowel adenocarcinomas.
  • Celiac disease-related and non-celiac disease-related small bowel adenocarcinomas displayed similar chromosomal aberrations.
  • Promoter hypermethylation of the APC gene was found in 48% non-celiac disease-related and 73% celiac disease-related small bowel adenocarcinomas.
  • Thirty-three percent of non-celiac disease-related small bowel adenocarcinomas showed microsatellite instability, whereas 67% of celiac disease-related small bowel adenocarcinomas were microsatellite unstable.
  • CONCLUSIONS: Our study characterized chromosomal aberrations and amplifications involved in small bowel adenocarcinoma.
  • At the chromosomal level, celiac disease-related and non-celiac disease-related small bowel adenocarcinomas did not differ.
  • A defect in the mismatch repair pathways seems to be more common in celiac disease-related than in non-celiac disease-related small bowel adenocarcinomas.
  • In contrast to colon and gastric cancers, no APC nonsense mutations were found in small bowel adenocarcinoma.
  • However, APC promoter methylation seems to be a common event in celiac disease-related small bowel adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Celiac Disease / complications. Intestinal Neoplasms / genetics

  • Genetic Alliance. consumer health - Celiac Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20179237.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


55. McGowan CE, Lagares-Garcia JA, Bhattacharya B: Retained capsule endoscope leading to the identification of small bowel adenocarcinoma in a patient with undiagnosed Crohn disease. Ann Diagn Pathol; 2009 Dec;13(6):390-3
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retained capsule endoscope leading to the identification of small bowel adenocarcinoma in a patient with undiagnosed Crohn disease.
  • Small intestinal neoplasia is a rare condition that frequently presents a diagnostic challenge.
  • We describe the case of a 70-year-old patient who presented with several years of chronic, intermittent abdominal pain, previously diagnosed as irritable bowel syndrome.
  • Radiographic evaluation, including upper gastrointestinal series with small bowel follow-through and computed tomography, demonstrated dilated small bowel with possible strictures.
  • Extensive flat and polypoid high- and low-grade dysplasia were present, as well as an area of well-differentiated adenocarcinoma invading into the muscularis propria.
  • We discuss the epidemiology, pathogenesis, and diagnosis of small bowel malignancy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Capsule Endoscopy. Crohn Disease / diagnosis. Ileal Neoplasms / diagnosis
  • [MeSH-minor] Abdominal Pain / diagnosis. Abdominal Pain / etiology. Aged. Humans. Male. Neoplasm Staging. Staining and Labeling. Treatment Outcome

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19917475.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Nicholl MB, Ahuja V, Conway WC, Vu VD, Sim MS, Singh G: Small bowel adenocarcinoma: understaged and undertreated? Ann Surg Oncol; 2010 Oct;17(10):2728-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small bowel adenocarcinoma: understaged and undertreated?
  • BACKGROUND: Primary small bowel adenocarcinoma (SBA) is a rare, chemoresistant tumor with an aggressive clinical nature.
  • [MeSH-major] Intestinal Neoplasms / pathology. Intestine, Small / pathology. Lymph Nodes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20458546.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


57. Zaanan A, Costes L, Gauthier M, Malka D, Locher C, Mitry E, Tougeron D, Lecomte T, Gornet JM, Sobhani I, Moulin V, Afchain P, Taïeb J, Bonnetain F, Aparicio T: Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study. Ann Oncol; 2010 Sep;21(9):1786-93
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study.
  • BACKGROUND: Small-bowel adenocarcinoma (SBA) is a rare tumor of poor prognosis.

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20223786.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


58. Eigenbrod T, Kullmann F, Klebl F: Resection of small bowel adenocarcinoma liver metastasis combined with neoadjuvant and adjuvant chemotherapy results in extended disease-free period--a case report. Int J Gastrointest Cancer; 2006;37(2-3):94-7
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection of small bowel adenocarcinoma liver metastasis combined with neoadjuvant and adjuvant chemotherapy results in extended disease-free period--a case report.
  • Small bowel adenocarcinoma (SBA) is a very rare tumor entity but occurs in up to 5% of patients suffering from familiar adenomatous polyposis (FAP).
  • Because of nonspecific symptoms, diagnosis is usually made with delay, which contributes to high rates of metastatic disease at the time of diagnosis.
  • In October 2001, a 51-year-old woman with attenuated FAP, that had total proctocolectomy in 1994 was diagnosed with a jejunal adenocarcinoma.
  • She subsequently underwent small bowel resection.
  • Afterwards, a small residual lesion in segment VIII was seen in CT scan but could not be identified by PET and at laparotomy in November 2002.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hepatectomy. Ileal Neoplasms / therapy. Jejunal Neoplasms / therapy. Liver Neoplasms / therapy. Neoadjuvant Therapy

  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17827529.001).
  • [ISSN] 1537-3649
  • [Journal-full-title] International journal of gastrointestinal cancer
  • [ISO-abbreviation] Int J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


59. Moon YW, Rha SY, Shin SJ, Chang H, Shim HS, Roh JK: Adenocarcinoma of the small bowel at a single Korean institute: management and prognosticators. J Cancer Res Clin Oncol; 2010 Mar;136(3):387-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the small bowel at a single Korean institute: management and prognosticators.
  • PURPOSE: Small bowel adenocarcinoma (SBA) is a rare malignancy with a poor outcome.
  • CONCLUSIONS: Early diagnosis is crucial to improve outcomes of SBA with respect to increasing resectability.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Intestinal Neoplasms / diagnosis. Intestinal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Algorithms. Chemotherapy, Adjuvant / methods. Chemotherapy, Adjuvant / utilization. Digestive System Surgical Procedures / methods. Female. Humans. Intestine, Small / pathology. Korea. Male. Middle Aged. Prognosis. Recurrence. Retrospective Studies. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19760196.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


60. Al-Amri A, Al-Quorain AA: Coexisting malignant lymphoma of the duodenum and adenocarcinoma of the colon. Saudi Med J; 2007 Mar;28(3):463-4
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexisting malignant lymphoma of the duodenum and adenocarcinoma of the colon.
  • Synchronous malignant mucosa associated lymphoid tissue MALT-lymphoma of the small bowel and adenocarcinoma of the colon in the same patient is a scarce rarity.
  • Thus, it might be of interest to report such a case of coexisting malignant MALT-lymphoma of the duodenum and adenocarcinoma of the large bowel.
  • [MeSH-major] Adenocarcinoma / pathology. Colonic Neoplasms / pathology. Duodenal Neoplasms / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Neoplasms, Multiple Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17334482.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


61. Ruiz-Tovar J, Martínez-Molina E, Morales V, Sanjuanbenito A: [Primary small bowel adenocarcinoma]. Cir Esp; 2009 Jun;85(6):354-9
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary small bowel adenocarcinoma].
  • [Transliterated title] Adenocarcinoma primario de intestino delgado.
  • INTRODUCTION: Primary small bowel adenocarcinoma is an uncommon tumour, with non-specific symptoms that cause a delay in the diagnosis and consequently a worse outcome for the patient.
  • MATERIAL AND METHOD: We performed a retrospective study of our experience with 17 patients diagnosed with primary small bowel adenocarcinoma, excluding all the cases suggesting secondary involvement of the small bowel from an adenocarcinoma in other locations.
  • Those with duodenal tumours underwent 4 pancreaticoduodenectomies, 3 gastroenterostomies and 1 diagnostic biopsy; 6 bowel resections with lymphadenectomy, 2 en-bloc resections and 1 by-pass were performed on those with jejuno-ileal tumours.
  • CONCLUSIONS: Curative treatment consists of small bowel resection.
  • [MeSH-major] Adenocarcinoma. Duodenal Neoplasms. Ileal Neoplasms. Jejunal Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19344893.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


62. Locher C, Malka D, Boige V, Lebray P, Elias D, Lasser P, Ducreux M: Combination chemotherapy in advanced small bowel adenocarcinoma. Oncology; 2005;69(4):290-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy in advanced small bowel adenocarcinoma.
  • OBJECTIVE: To assess the efficacy of 5-fluorouracil (5-FU) and either platinum compounds or irinotecan in patients with advanced small bowel adenocarcinoma (SBA), for whom data on the efficacy of chemotherapy are scarce.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Intestinal Neoplasms / drug therapy. Intestine, Small

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 16282708.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


63. Lee CH, Kim PS, Lee JI, Jeong S, Lee JW, Kwon KS, Lee DH, Kim HG, Shin YW, Kim YS, Kim JM, Jeon YS: [A case of primary jejunal adenocarcinoma diagnosed by enteroscopy using pediatric colonoscope]. Korean J Gastroenterol; 2006 Nov;48(5):365-8
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary jejunal adenocarcinoma diagnosed by enteroscopy using pediatric colonoscope].
  • Endoscopic jejunal biopsy showed moderately differentiated adenocarcinoma.
  • Small intestinal adenocarcinoma is uncommonly encountered in clinical practice.
  • Because small intestine is relatively inaccessible via routine endoscopy, diagnosis of small intestinal neoplasm is often delayed for several months after the onset of symptoms.
  • Therefore, when a small bowel neoplasm is suspected, enteroscopy is the most useful study.
  • If enteroscope is not available, enteroscopy using pediatric colonoscope may permit earlier preoperative diagnosis.
  • We report a case of primary jejunal adenocarcinoma diagnosed by endoscopic biopsy using pediatric colonoscope.
  • [MeSH-major] Adenocarcinoma / pathology. Jejunal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17132927.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


64. Menon AM, Mirza AH, Moolla S, Morton DG: Adenocarcinoma of the small bowel arising from a previous strictureplasty for Crohn's disease: report of a case. Dis Colon Rectum; 2007 Feb;50(2):257-9
MedlinePlus Health Information. consumer health - Crohn's Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the small bowel arising from a previous strictureplasty for Crohn's disease: report of a case.
  • Small-bowel adenocarcinoma is an uncommon tumor, comprising<2 percent of all gastrointestinal tract malignancies.
  • To date, there have been only two documented cases of adenocarcinoma arising at the site of previous strictureplasty reported in the literature.
  • We report the third such case in a patient with no other premalignant conditions affecting the small bowel and question whether we may see an increasing trend in this type of presentation.
  • [MeSH-major] Adenocarcinoma / pathology. Crohn Disease / pathology. Crohn Disease / surgery. Intestinal Neoplasms / pathology. Intestine, Small / pathology

  • Genetic Alliance. consumer health - Crohn Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17180254.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Suenaga M, Mizunuma N, Chin K, Matsusaka S, Shinozaki E, Oya M, Ueno M, Yamaguchi T, Muto T, Konishi F, Hatake K: Chemotherapy for small-bowel Adenocarcinoma at a single institution. Surg Today; 2009;39(1):27-31
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for small-bowel Adenocarcinoma at a single institution.
  • PURPOSE: Small-bowel adenocarcinoma (SBA) is rare.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Intestinal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Camptothecin / administration & dosage. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Disease Progression. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Follow-Up Studies. Humans. Intestine, Small / radiography. Leucovorin / administration & dosage. Leucovorin / adverse effects. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed. Vitamin B Complex / administration & dosage. Vitamin B Complex / adverse effects

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19132464.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 12001-76-2 / Vitamin B Complex; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


66. Moran JA, Lemberger K, Cadoré JL, Lepage OM: Small intestine adenocarcinoma in conjunction with multiple adenomas causing acute colic in a horse. J Vet Diagn Invest; 2008 Jan;20(1):121-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small intestine adenocarcinoma in conjunction with multiple adenomas causing acute colic in a horse.
  • An 11-year-old Andalusian stallion developed marked signs of colic associated with an acute small intestine obstruction.
  • Exploratory laparotomy revealed a distal jejunum full-thickness wall induration and multiple small adherent intraluminal masses.
  • Histologic examination revealed an adenocarcinoma and multiple polypoid adenomas.
  • Colic was considered secondary to partial jejunal lumen obstruction by the adenocarcinoma.
  • Adenocarcinoma recurrence or transformation from remaining adenomas into an adenocarcinoma is still a major risk.
  • [MeSH-major] Adenocarcinoma / veterinary. Colic / veterinary. Horse Diseases / pathology. Intestinal Neoplasms / veterinary. Intestine, Small / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18182527.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Overman MJ, Varadhachary GR, Kopetz S, Adinin R, Lin E, Morris JS, Eng C, Abbruzzese JL, Wolff RA: Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol; 2009 Jun 1;27(16):2598-603
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.
  • PURPOSE: Adenocarcinomas of the small bowel and ampulla of Vater represent rare cancers that have limited data regarding first-line therapy.
  • We conducted a phase II trial to evaluate the benefit of capecitabine in combination with oxaliplatin (CAPOX) in patients with advanced adenocarcinoma of small bowel or ampullary origin.
  • CAPOX should be considered a new standard regimen for advanced small bowel and ampullary adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / drug therapy. Ampulla of Vater / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Common Bile Duct Neoplasms / drug therapy. Intestinal Neoplasms / drug therapy. Intestine, Small / pathology

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19164203.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


68. Garrido A, Luque A, Vázquez A, Hernández JM, Alcántara F, Márquez JL: [Primary small bowel neoplasms as a complication of celiac disease]. Gastroenterol Hepatol; 2009 Nov;32(9):618-21
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary small bowel neoplasms as a complication of celiac disease].
  • [Transliterated title] Neoplasias primarias de intestino delgado como complicación de la enfermedad celíaca.
  • The most serious complication in these patients is the development of neoplasms, the most frequent being enteropathy-associated T-cell lymphoma; however, an increase in the incidence of small bowel adenocarcinoma has also been described.
  • We present two cases of small bowel carcinoma in patients with celiac disease, which were diagnosed at the onset of the disease.
  • [MeSH-major] Adenocarcinoma / etiology. Celiac Disease / complications. Duodenal Neoplasms / etiology. Ileal Neoplasms / etiology

  • Genetic Alliance. consumer health - Celiac Disease.
  • MedlinePlus Health Information. consumer health - Celiac Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19625106.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


69. Breuhahn K, Singh S, Schirmacher P, Bläker H: Large-scale N-terminal deletions but not point mutations stabilize beta-catenin in small bowel carcinomas, suggesting divergent molecular pathways of small and large intestinal carcinogenesis. J Pathol; 2008 Jul;215(3):300-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large-scale N-terminal deletions but not point mutations stabilize beta-catenin in small bowel carcinomas, suggesting divergent molecular pathways of small and large intestinal carcinogenesis.
  • Small intestinal adenocarcinoma is rare and its molecular pathogenesis is incompletely understood.
  • In order to elucidate the molecular background of beta-catenin stabilization in small intestinal adenocarcinoma, we investigated 20 non-familial adenomatous polyposis coli (FAP)-associated tumours, including five microsatellite-unstable carcinomas for beta-catenin alterations, by immunohistochemistry, western blot analysis and sequence analysis on the RNA and DNA levels.
  • Our data show that large intragenic CTNNB1 mutations stabilize beta-catenin in small intestinal adenocarcinomas and influence the subcellular distribution of the protein.
  • In contrast to colon carcinomas, neither APC nor CTNNB1 point mutations seem to play a significant role in carcinogenesis, indicating divergent mechanisms of wnt/wingless control in the small and the large intestine.
  • [MeSH-major] Adenocarcinoma / genetics. Intestinal Neoplasms / genetics. Sequence Deletion. beta Catenin / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 Pathological Society of Great Britain and Ireland.
  • (PMID = 18491352.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / Wnt Proteins; 0 / beta Catenin
  •  go-up   go-down


70. Kim HK, Ko BM, Park JK, Hong SJ, Moon JH, Lee JS, Lee MS, Kim BS: [A case of locally invasive obstructive jejunal cancer with curative resection after stenting and chemotherapy]. Korean J Gastroenterol; 2010 Jul;56(1):54-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Small bowel adenocarcinoma is a relatively rare malignancy.
  • In Korea, 13.1% of small bowel adenocarcinoma occurs in the jejunum.
  • The absence of effective screening methods and relatively obscure symptoms contribute to the higher percentage of advanced cases at the time of diagnosis.
  • Chemotherapy and radiotherapy have shown a disappointing treatment result for advanced staged small bowel adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Intestinal Obstruction / diagnosis. Jejunal Neoplasms / diagnosis. Stents

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20664318.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


71. Vagholkar K, Mathew T: Adenocarcinoma of the small bowel: a surgical dilemma. Saudi J Gastroenterol; 2009 Oct-Dec;15(4):264-7
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the small bowel: a surgical dilemma.
  • Malignant tumors of the small intestine are among the rarest types of gastrointestinal cancers.
  • Due to their infrequent occurrence and the multitude of tumor types (viz, adenocarcinomas, carcinoids, sarcomas, and lymphomas), not much is known about their natural history and presentation, and there is often delay in the diagnosis.
  • Adenocarcinoma is the commonest histologic type of small bowel cancer.
  • In this article, a case of adenocarcinoma of the jejunum presenting as an abdominal lump is presented, along with a review of the literature.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Jejunal Neoplasms / pathology. Jejunal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dig Dis. 1996 Jul-Aug;14(4):245-57 [8843980.001]
  • [Cites] Ann Surg Oncol. 1994 May;1(3):183-8 [7842287.001]
  • [Cites] Am J Surg. 1997 Mar;173(3):237-9 [9124635.001]
  • [Cites] Oncology (Williston Park). 1997 Apr;11(4):529-36; discussion 545, 549-50 [9130275.001]
  • [Cites] J Comput Assist Tomogr. 1997 Nov-Dec;21(6):986-91 [9386295.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Mar;7(3):243-51 [9521441.001]
  • [Cites] J Am Coll Surg. 1998 Jun;186(6):664-8 [9632155.001]
  • [Cites] Cancer. 1998 Jul 15;83(2):240-4 [9669805.001]
  • [Cites] Br J Cancer. 1998 Aug;78(4):508-10 [9716035.001]
  • [Cites] J Gastrointest Surg. 1998 Jan-Feb;2(1):79-87 [9841972.001]
  • [Cites] World J Surg Oncol. 2008;6:12 [18237404.001]
  • [Cites] World J Surg. 2000 Apr;24(4):421-9 [10706914.001]
  • [Cites] Gastroenterology. 2002 Oct;123(4):999-1005 [12360460.001]
  • [Cites] Mod Pathol. 2003 Feb;16(2):130-6 [12591965.001]
  • [Cites] Med J Aust. 2003 Jun 2;178(11):537-40 [12765499.001]
  • [Cites] Tumori. 2003 Mar-Apr;89(2):193-5 [12841670.001]
  • [Cites] J Chemother. 2003 Oct;15(5):503-6 [14598944.001]
  • [Cites] Hum Pathol. 2003 Oct;34(10):1048-52 [14608540.001]
  • [Cites] Cancer. 1984 Jan 1;53(1):23-5 [6690001.001]
  • [Cites] Am J Surg. 1984 Jan;147(1):66-71 [6691554.001]
  • [Cites] AJR Am J Roentgenol. 1989 Oct;153(4):741-4 [2672733.001]
  • [Cites] Am J Gastroenterol. 1991 Mar;86(3):304-8 [1998312.001]
  • [Cites] Gastroenterology. 1992 Jun;102(6):1980-2 [1316858.001]
  • [Cites] Cancer Causes Control. 1993 Mar;4(2):163-9 [8481495.001]
  • [Cites] Int J Cancer. 1997 Feb 7;70(4):390-5 [9033644.001]
  • (PMID = 19794274.001).
  • [ISSN] 1998-4049
  • [Journal-full-title] Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
  • [ISO-abbreviation] Saudi J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  • [Other-IDs] NLM/ PMC2981845
  •  go-up   go-down


72. Agrawal S, McCarron EC, Gibbs JF, Nava HR, Wilding GE, Rajput A: Surgical management and outcome in primary adenocarcinoma of the small bowel. Ann Surg Oncol; 2007 Aug;14(8):2263-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical management and outcome in primary adenocarcinoma of the small bowel.
  • BACKGROUND: Primary adenocarcinoma of the small bowel is a rare malignancy and is associated with poor survival outcome.
  • METHODS: Between 1971 and 2005, 64 patients with primary adenocarcinoma of the small bowel were treated at our institution.
  • RESULTS: The most common clinical features at presentation included abdominal pain (n = 33; 51.6%) or bowel obstruction (n = 20; 31.3%).
  • The most frequently involved portion of the small bowel was the duodenum (n = 41; 64%).
  • A segmental bowel resection was performed in 30 patients and pancreaticoduodenectomy in 14 patients.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Intestinal Neoplasms / diagnosis. Intestinal Neoplasms / pathology. Intestinal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17549572.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Farrell S, Gray SB, Best BG: Mucusuria--an unusual manifestation of ileal adenocarcinoma: a case report and review of the literature. Int Surg; 2005 Apr-Jun;90(2):85-7
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucusuria--an unusual manifestation of ileal adenocarcinoma: a case report and review of the literature.
  • Primary adenocarcinoma of the ileum is an uncommon gastrointestinal malignancy, the symptoms of which are often insidious in onset.
  • This case history highlights the previously unreported finding of ileal adenocarcinoma presenting with mucusuria, caused by local invasion of the bladder in a 44-year-old male.
  • A review of the literature is included to highlight the incidence, risk factors, clinical presentation, investigation, and current management of adenocarcinoma of the small bowel.
  • [MeSH-major] Adenocarcinoma / secondary. Ileal Neoplasms / pathology. Intestinal Fistula / diagnosis. Urinary Bladder Fistula / diagnosis. Urinary Bladder Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16119711.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


74. Saurin JC, Pilleul F, Soussan EB, Manière T, D'Halluin PN, Gaudric M, Cellier C, Heresbach D, Gaudin JL, Capsule Commission of the French Society of Digestive Endoscopy (SFED): Small-bowel capsule endoscopy diagnoses early and advanced neoplasms in asymptomatic patients with Lynch syndrome. Endoscopy; 2010 Dec;42(12):1057-62
Genetic Alliance. consumer health - Lynch syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small-bowel capsule endoscopy diagnoses early and advanced neoplasms in asymptomatic patients with Lynch syndrome.
  • BACKGROUND AND STUDY AIMS: Patients with Lynch syndrome are at increased risk of developing small-bowel adenocarcinoma, which usually has a bad prognosis and needs to be diagnosed early.
  • RESULTS: Histologically confirmed small-bowel neoplasms were diagnosed in three patients (8.6 %): one adenocarcinoma (T3N0M0) and two adenomas with low-grade dysplasia.
  • CT enteroclysis raised suspicion of one neoplasm (adenocarcinoma) but missed the two others.
  • The clinical usefulness of systematic small-bowel screening in these patients should be confirmed through large prospective studies.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Capsule Endoscopy. Colorectal Neoplasms, Hereditary Nonpolyposis / complications. Intestinal Neoplasms / diagnosis. Intestine, Small

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Georg Thieme Verlag KG Stuttgart · New York.
  • (PMID = 20821360.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


75. Overman MJ, Kopetz S, Wen S, Hoff PM, Fogelman D, Morris J, Abbruzzese JL, Ajani JA, Wolff RA: Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. Cancer; 2008 Oct 15;113(8):2038-45
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma.
  • BACKGROUND: Metastatic small bowel adenocarcinoma (SBA) has a poor prognosis.
  • The primary tumor site was the jejunum in 35 patients (43%), duodenum in 30 patients (38%), ileum in 6 patients (8%), and nonspecified small bowel in 9 patients (11%).
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Intestinal Neoplasms / drug therapy. Intestine, Small / pathology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • (PMID = 18759326.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Platinum Compounds; U3P01618RT / Fluorouracil
  •  go-up   go-down


76. Yamano T, Morii E, Arai I, Takada T, Aozasa K: Successful treatment of recurrent small bowel adenocarcinoma by cytoreductive surgery and chemotherapy: a case report and review of the literature. J Med Case Rep; 2010;4:213

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of recurrent small bowel adenocarcinoma by cytoreductive surgery and chemotherapy: a case report and review of the literature.
  • INTRODUCTION: Small bowel adenocarcinoma is a rare malignancy associated with a poor prognosis and there is little evidence of effective treatment.
  • Recurrent small bowel adenocarcinoma is an intractable disease for which there is little information available regarding its treatment by palliative therapy.
  • We present a case of recurrent small bowel adenocarcinoma successfully treated by cytoreductive surgery and palliative chemotherapy.
  • CASE PRESENTATION: We report the case of a 72-year-old Japanese female who developed a peritoneal metastasis from recurrent small bowel adenocarcinoma after curative resection and adjuvant chemotherapy with S-1 and polysaccharide K.
  • CONCLUSION: To the best of our knowledge, this is the first case report of the successful treatment of peritoneal metastasis from small bowel adenocarcinoma by cytoreductive surgery and combination chemotherapy (folinic acid/fluorouracil/oxaliplatin and folinic acid/fluorouracil/irinotecan with polysaccharide K).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Immunol Immunother. 2007 Jun;56(6):905-11 [17106715.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(3):CD005202 [17636789.001]
  • [Cites] Am J Clin Oncol. 2006 Jun;29(3):225-31 [16755174.001]
  • [Cites] Cancer Immunol Immunother. 2006 Apr;55(4):404-11 [16133112.001]
  • [Cites] Oncology. 2005;69(4):290-4 [16282708.001]
  • [Cites] J Surg Oncol. 2005 Aug 1;91(2):112-7; discussion 118-9 [16028284.001]
  • [Cites] Oncologist. 2005 Feb;10(2):132-7 [15709215.001]
  • [Cites] Surg Clin North Am. 1986 Aug;66(4):779-85 [3738698.001]
  • [Cites] Am J Surg Pathol. 2004 Oct;28(10):1352-9 [15371952.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):518-26 [15274064.001]
  • [Cites] J Chemother. 2003 Oct;15(5):503-6 [14598944.001]
  • [Cites] Eur J Surg Oncol. 2002 Feb;28(1):19-23 [11869008.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2693-706 [10594865.001]
  • [Cites] Gastrointest Cancer Res. 2009 May;3(3):121-2 [19626156.001]
  • [Cites] Gastrointest Cancer Res. 2009 May;3(3):90-6 [19626152.001]
  • [Cites] J Clin Oncol. 2009 Jun 1;27(16):2598-603 [19164203.001]
  • [Cites] Cancer. 2008 Oct 15;113(8):2038-45 [18759326.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1810-20 [17978289.001]
  • [Cites] J Am Coll Surg. 2007 May;204(5):943-53; discussion 953-5 [17481516.001]
  • (PMID = 20637117.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2917439
  •  go-up   go-down


77. Chua TC, Koh JL, Yan TD, Liauw W, Morris DL: Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from small bowel adenocarcinoma. J Surg Oncol; 2009 Aug 1;100(2):139-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from small bowel adenocarcinoma.
  • BACKGROUND: Small bowel adenocarcinoma is a rare malignancy that presents both a diagnostic and therapeutic challenge.
  • We review our experience with small bowel peritoneal carcinomatosis following treatment with cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy (PIC).
  • METHODS: From a prospective database of CRS and PIC, seven patients were identified to have undergone treatment for small bowel peritoneal carcinomatosis with CRS and hyperthermic intraperitoneal chemotherapy (Mitomycin C) and early postoperative intraperitoneal chemotherapy (5FU).
  • Tumor histology of poorly differentiated adenocarcinoma with signet ring, lymphovascular invasion and perineural invasion appeared to be associated with a poor outcome.
  • CONCLUSION: Cytoreductive surgery and perioperative intraperitoneal chemotherapy is a treatment option for small bowel cancer peritoneal carcinomatosis with encouraging survival results.
  • [MeSH-major] Adenocarcinoma / therapy. Hyperthermia, Induced. Ileal Neoplasms / therapy. Jejunal Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19544356.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Gao C, Wang AY: Significance of increased apoptosis and Bax expression in human small intestinal adenocarcinoma. J Histochem Cytochem; 2009 Dec;57(12):1139-48

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of increased apoptosis and Bax expression in human small intestinal adenocarcinoma.
  • Human small intestine accounts for 75% of the gastrointestinal (GI) length but for only 1-5% of GI tumors.
  • For this purpose, 77 samples from patients were examined by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling and immunohistochemistry, including 40 cases from normal small intestine (jejunum), 7 cases from jejunum and ileum adenocarcinomas, and 30 cases from normal colon.
  • The results showed that a significantly higher level of enterocyte apoptosis was observed in normal small intestine compared with small intestinal adenocarcinomas and normal colon (median of apoptotic index, 15.2% vs 0.1% and 1.6%, p<0.01).
  • In conclusion, increased apoptosis and expression of Bax, not Bcl-2 or the Bax/Bcl-2 ratio, may play some role in the relatively lower incidence of human small intestinal carcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Apoptosis. Gene Expression Regulation, Neoplastic. Intestinal Neoplasms / pathology. Intestine, Small / metabolism. Intestine, Small / pathology. bcl-2-Associated X Protein / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Gastroenterol. 1999 Nov;34(11):1162-7 [10582770.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2008 Jul;16(4):393-9 [18528276.001]
  • [Cites] Nature. 2001 Jul 5;412(6842):23 [11452281.001]
  • [Cites] Ital J Anat Embryol. 2001;106(2 Suppl 1):353-61 [11729977.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2001 Dec;9(4):329-34 [11759059.001]
  • [Cites] Gerontology. 2002 Jul-Aug;48(4):204-8 [12053108.001]
  • [Cites] Cancer. 2002 Oct 1;95(7):1463-71 [12237915.001]
  • [Cites] Cancer Lett. 2004 Jan 20;203(2):181-90 [14732226.001]
  • [Cites] Cell. 1993 Aug 27;74(4):609-19 [8358790.001]
  • [Cites] Science. 1995 Mar 10;267(5203):1456-62 [7878464.001]
  • [Cites] Cancer Res. 1995 May 1;55(9):1811-6 [7728743.001]
  • [Cites] Arch Histol Cytol. 1995 Jun;58(2):205-19 [7576872.001]
  • [Cites] Gut. 1996 Dec;39(6):811-7 [9038662.001]
  • [Cites] Nature. 1998 Jan 29;391(6666):496-9 [9461218.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1322-6 [9735050.001]
  • [Cites] Gastroenterology. 2005 Mar;128(3):590-9 [15765394.001]
  • [Cites] Histochem Cell Biol. 2005 Mar;123(3):249-61 [15765213.001]
  • [Cites] Pathology. 2005 Feb;37(1):56-62 [15875735.001]
  • [Cites] Exp Biol Med (Maywood). 2005 Jul;230(7):464-71 [15985621.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 Nov;33(12):1723-5 [17212087.001]
  • [Cites] Hematology. 2007 Feb;12(1):39-43 [17364991.001]
  • [Cites] Ann N Y Acad Sci. 2007 Jan;1095:53-61 [17404017.001]
  • [Cites] Apoptosis. 2007 May;12(5):887-96 [17453158.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(3):CD005202 [17636789.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Dec;15(4):401-6 [18091382.001]
  • [Cites] Gut. 2000 Nov;47(5):632-7 [11034578.001]
  • (PMID = 19729672.001).
  • [ISSN] 1551-5044
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / bcl-2-Associated X Protein
  • [Other-IDs] NLM/ PMC2778087
  •  go-up   go-down


79. Beaugerie L, Sokol H, Seksik P: Noncolorectal malignancies in inflammatory bowel disease: more than meets the eye. Dig Dis; 2009;27(3):375-81
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Noncolorectal malignancies in inflammatory bowel disease: more than meets the eye.
  • In patients with Crohn's disease, the risk of small bowel adenocarcinoma is 20-40 times higher than the low background risk of the general population.
  • In the subset of patients with longstanding small bowel lesions, the absolute risk of small bowel adenocarcinoma exceeds 1 per 100 patient-years after 25 years of follow-up and becomes equivalent to the risk of colorectal cancer.
  • Growing evidence suggests that the pathogenesis of small bowel adenocarcinoma arising in inflammatory lesions of Crohn's disease is similar to that of colorectal cancer complicating chronic colonic inflammation (inflammation-dysplasia-cancer sequence).
  • However, contrasting with the established endoscopic detection of colonic advanced neoplasias in patients with longstanding extensive colitis, there is no consensus at this time how to face the excess-risk of small bowel adenocarcinoma in patients at high risk.
  • There are no specific clinical or imaging alert signs and endoscopic surveillance of the totality of the inflamed small bowel mucosa would suppose to perform repeated enteroscopies, with the potential limiting factor of stenosis.
  • Data from referral centers and from the CESAME cohort suggest that intestinal lymphomas may arise in the chronically inflamed segments in patients with inflammatory bowel disease (IBD).
  • [MeSH-major] Colorectal Neoplasms / complications. Inflammatory Bowel Diseases / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19786768.001).
  • [ISSN] 1421-9875
  • [Journal-full-title] Digestive diseases (Basel, Switzerland)
  • [ISO-abbreviation] Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 46
  •  go-up   go-down


80. Friedrich-Rust M, Ell C: Early-stage small-bowel adenocarcinoma: a review of local endoscopic therapy. Endoscopy; 2005 Aug;37(8):755-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early-stage small-bowel adenocarcinoma: a review of local endoscopic therapy.
  • Early adenocarcinomas in the small intestine are a rare entity.
  • Most adenocarcinomas in the small intestine are diagnosed at a more advanced stage.
  • After surgical resection, only 3 - 10 % are found in stage T1 and 0 - 3 % in stage Tis (high-grade intraepithelial neoplasia), resulting in an overall 3 - 13 % rate of early-stage small-intestinal adenocarcinomas.
  • The diagnosis of early small-intestinal carcinoma by endoscopy is still very rare, although it will probably improve with the development of new endoscopic techniques.
  • [MeSH-major] Adenocarcinoma / surgery. Endoscopy, Gastrointestinal. Intestinal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16032496.001).
  • [ISSN] 0013-726X
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 68
  •  go-up   go-down


81. Iwata T, Inoue K, Kiriike S, Izumi N, Mizuguchi S, Tsukioka T, Morita R, Nishiyama N, Takemura M, Osugi H, Wakasa K, Suehiro S: Hemorrhagic small intestine cancer with solitary pulmonary metastasis initially presented as suspected primary lung cancer: an autopsy report. Osaka City Med J; 2007 Dec;53(2):109-16
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemorrhagic small intestine cancer with solitary pulmonary metastasis initially presented as suspected primary lung cancer: an autopsy report.
  • Cancer of the small intestine presenting with a solitary pulmonary metastasis is rare.
  • Diagnosis and treatment of hemorrhagic small intestinal disease is clinically problematic due to its anatomic aspect, especially after multiple laparotomies.
  • During the preoperative evaluation period, massive intestinal hemorrhage occurred.
  • Intestinal tumor was identified by double-balloon enteroscopy and emergency laparotomy was performed to control the bleeding.
  • The histopathological diagnosis was metastatic adenocarcinoma.
  • However, intestinal bleeding started again.
  • Autopsy revealed a large polypoid tumor with hemorrhagic necrosis in the jejunum that was histologically and immunohistochemically diagnosed as primary poorly differentiated adenocarcinoma in the small intestine.
  • Multiple small submucosal tumors with central ulceration were confirmed as intramural metastases.
  • In the diagnosis and treatment of the disease, we faced several clinically difficult problems.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / secondary. Gastrointestinal Hemorrhage / etiology. Jejunal Neoplasms / complications. Jejunal Neoplasms / secondary. Lung Neoplasms / pathology


82. Caruso S, Marrelli D, Pedrazzani C, Neri A, Mazzei MA, Onorati M, Corso G, Cerullo G, Roviello F: A rare case of primary small bowel adenocarcinoma with intussusception. Tumori; 2010 Mar-Apr;96(2):355-7
MedlinePlus Health Information. consumer health - Small Intestine Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of primary small bowel adenocarcinoma with intussusception.
  • In contrast with the colon tract, the incidence of primary malignancies in the small bowel is very low.
  • We report the case of a 51-year-old man presenting with jejunal intussusception due to a primary adenocarcinoma.
  • The patient was referred to our division for bowel obstruction.
  • Histological examination of the specimen resulted in a diagnosis of a primary adenocarcinoma of the small bowel.
  • In adult intestinal intussusception, resection without reduction is considered the optimal management if an underlying primary malignancy cannot be excluded.
  • [MeSH-major] Adenocarcinoma / complications. Intussusception / etiology. Jejunal Diseases / etiology. Jejunal Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20572601.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


83. Sameshima S, Tomozawa S, Koketsu S, Okada T, Miyato H, Iijima M, Kojima M, Kaji T: Intramucosal adenocarcinoma of the ileum originated 40 years after ileosigmoidostomy. World J Surg Oncol; 2009;7:41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intramucosal adenocarcinoma of the ileum originated 40 years after ileosigmoidostomy.
  • BACKGROUND: Small bowel adenocarcinomas (SBAs) are rare carcinomas.
  • A mucosal biopsy specimen showed adenocarcinoma histopathologically.
  • Histological examination revealed a well differentiated intramucosal adenocarcinoma (adenocarcinoma in situ).
  • Immunohistological staining demonstrated the overexpression of p53 protein in the adenocarcinoma.
  • CONCLUSION: Adenocarcinoma of the ileum at such an early stage is a very rare event.
  • In this case, there is a possibility that the ileosigmoidostomy resulted in a back flow of colonic stool to the ileum that caused the carcinogenesis of the small intestine.
  • [MeSH-major] Adenocarcinoma / etiology. Appendicitis / surgery. Colon, Sigmoid / surgery. Ileal Neoplasms / etiology. Ileostomy / adverse effects. Postoperative Complications / etiology

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Appendicitis.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Colorectal Dis. 2003 May;18(3):276-8 [12785331.001]
  • [Cites] Dis Colon Rectum. 2002 Nov;45(11):1496-502 [12432298.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):518-26 [15274064.001]
  • [Cites] Arch Pathol Lab Med. 1982 Jun;106(6):308-9 [6896439.001]
  • [Cites] Hum Pathol. 1983 Nov;14(11):931-68 [6629368.001]
  • [Cites] Dis Colon Rectum. 1985 Jun;28(6):383-8 [4006632.001]
  • [Cites] Ann Surg. 1989 Jun;209(6):764-73 [2543338.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Int J Clin Pract Suppl. 2005 Apr;(147):106-8 [15875642.001]
  • [Cites] Endoscopy. 2005 Aug;37(8):755-9 [16032496.001]
  • [Cites] Cancer Causes Control. 2005 Sep;16(7):781-7 [16132788.001]
  • [Cites] Int J Colorectal Dis. 2006 Jul;21(5):478-82 [16365680.001]
  • [Cites] Am J Gastroenterol. 2006 Jul;101(7):1647-54 [16863573.001]
  • [Cites] Dig Dis Sci. 2008 Feb;53(2):474-80 [17676397.001]
  • [Cites] Dis Colon Rectum. 2009 Mar;52(3):538-41 [19333060.001]
  • [Cites] Dis Colon Rectum. 2000 Jan;43(1):101-4 [10813131.001]
  • [Cites] Int J Colorectal Dis. 2001 Apr;16(2):126-30 [11355319.001]
  • [Cites] World J Surg. 2002 Mar;26(3):390-6 [11865380.001]
  • [Cites] Am J Gastroenterol. 2003 Jun;98(6):1423-7 [12818291.001]
  • (PMID = 19379525.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2676285
  •  go-up   go-down


84. Kalogerinis PT, Poulos JE, Morfesis A, Daniels A, Georgakila S, Daignualt T, Georgakilas AG: Duodenal carcinoma at the ligament of Treitz. A molecular and clinical perspective. BMC Gastroenterol; 2010;10:109
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: There is very small occurrence of adenocarcinoma in the small bowel.
  • We present a case of primary duodenal adenocarcinoma and discuss the findings of the case diagnostic modalities, current knowledge on the molecular biology behind small bowel neoplasms and treatment options.
  • CASE: The patient had a history of iron deficiency anemia and occult bleeding with extensive workup consisting of upper endoscopy, colonoscopy, capsule endoscopy, upper gastrointestinal series with small bowel follow through and push enteroscopy.
  • Due to persistent abdominal pain and iron deficiency anemia the patient underwent push enteroscopy which revealed adenocarcinoma of the duodenum.
  • The patient underwent en-bloc duodenectomy which revealed T3N1M0 adenocarcinoma of the 4th portion of the duodenum.
  • CONCLUSIONS: Primary duodenal carcinoma, although rare should be considered in the differential diagnosis of occult gastrointestinal bleeding when evaluation of the lower and upper GI tract is unremarkable.
  • We discuss the current evaluation and management of this small bowel neoplasm.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Duodenal Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Duodenoscopy. Female. Humans. Laparotomy. Ligaments. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dig Dis Sci. 2008 Aug;53(8):2140-3 [18270840.001]
  • [Cites] Gastrointest Endosc. 2008 May;67(6):890-7 [18178204.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Nov;6(11):1202-5 [18799359.001]
  • [Cites] Gastrointest Endosc. 2008 Dec;68(6):1117-21 [19028219.001]
  • [Cites] Gastrointest Endosc. 2008 Dec;68(6):1209-14 [19028234.001]
  • [Cites] Ann Surg. 2009 Jan;249(1):63-71 [19106677.001]
  • [Cites] Gastrointest Endosc. 2009 Apr;69(4):866-74 [19136098.001]
  • [Cites] Pediatr Blood Cancer. 2009 Jul;53(1):116-20 [19283792.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2009 Jul;19(3):349-56 [19647644.001]
  • [Cites] J Gastrointest Cancer. 2009;40(1-2):33-7 [19513860.001]
  • [Cites] World J Gastroenterol. 2009 Dec 28;15(48):6075-9 [20027680.001]
  • [Cites] Gastroenterology. 2000 Jan;118(1):201-21 [10611170.001]
  • [Cites] Am Surg. 2000 Jan;66(1):46-51 [10651347.001]
  • [Cites] Am J Surg. 2000 Jan;179(1):37-41 [10737576.001]
  • [Cites] Gastroenterology. 2000 Dec;119(6):1431-8 [11113063.001]
  • [Cites] J Clin Gastroenterol. 2001 Oct;33(4):267-82 [11588539.001]
  • [Cites] Gut. 2002 Feb;50(2):218-23 [11788563.001]
  • [Cites] Endoscopy. 2002 Sep;34(9):685-9 [12195324.001]
  • [Cites] Arch Surg. 2003 Jan;138(1):80-5 [12511157.001]
  • [Cites] QJM. 2003 May;96(5):345-53 [12702783.001]
  • [Cites] Isr Med Assoc J. 2003 Mar;5(3):188-92 [12725140.001]
  • [Cites] Endoscopy. 2003 Dec;35(12):1009-14 [14648412.001]
  • [Cites] Gut. 2004 Feb;53(2):261-5 [14724161.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):493-8 [14752072.001]
  • [Cites] Chin Med J (Engl). 2004 Jul;117(7):1045-9 [15265380.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):518-26 [15274064.001]
  • [Cites] Ann Surg. 1974 Aug;180(2):175-9 [4843046.001]
  • [Cites] Cancer. 1984 Jan 1;53(1):23-5 [6690001.001]
  • [Cites] Cancer Res. 1989 Sep 1;49(17):4682-9 [2547513.001]
  • [Cites] Dig Dis Sci. 1992 Aug;37(8):1179-84 [1499440.001]
  • [Cites] Cancer Causes Control. 1993 Mar;4(2):163-9 [8481495.001]
  • [Cites] Am J Gastroenterol. 1994 May;89(5):699-701 [8172140.001]
  • [Cites] Am J Gastroenterol. 1994 Dec;89(12):2139-42 [7977229.001]
  • [Cites] Br J Surg. 1994 Oct;81(10):1472-4 [7820475.001]
  • [Cites] Am Surg. 1995 Aug;61(8):698-702; discussion 702-3 [7618809.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Jul 15;82(2):146-50 [7664244.001]
  • [Cites] Int J Cancer. 1997 Feb 7;70(4):390-5 [9033644.001]
  • [Cites] Ann Surg. 1997 Mar;225(3):300-6 [9060587.001]
  • [Cites] Oncology (Williston Park). 1997 Apr;11(4):529-36; discussion 545, 549-50 [9130275.001]
  • [Cites] AJR Am J Roentgenol. 1997 Dec;169(6):1545-50 [9393162.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Mar;7(3):243-51 [9521441.001]
  • [Cites] Br J Cancer. 1998 Aug;78(4):508-10 [9716035.001]
  • [Cites] Int J Cancer. 1999 Jul 19;82(2):171-4 [10389747.001]
  • [Cites] Am J Gastroenterol. 1999 Jul;94(7):1884-7 [10406253.001]
  • [Cites] Radiology. 2004 Nov;233(2):338-44 [15459329.001]
  • [Cites] Gastrointest Endosc. 2004 Nov;60(5):711-3 [15557946.001]
  • [Cites] J Clin Gastroenterol. 2005 Jan;39(1):36-41 [15599208.001]
  • [Cites] Cancer Causes Control. 2005 Sep;16(7):781-7 [16132788.001]
  • [Cites] Endoscopy. 2005 Oct;37(10):960-5 [16189768.001]
  • [Cites] World J Gastroenterol. 2006 Mar 21;12(11):1802-4 [16586559.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2006 Apr;16(2):363-76 [16644464.001]
  • [Cites] Endoscopy. 2006 May;38(5):542 [16586243.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):22-7 [16736516.001]
  • [Cites] Gastrointest Endosc. 2006 Sep;64(3):445-9 [16923502.001]
  • [Cites] Gastrointest Endosc. 2006 Nov;64(5):740-50 [17055868.001]
  • [Cites] Radiology. 2006 Dec;241(3):796-801 [17053201.001]
  • [Cites] Arch Surg. 2007 Mar;142(3):229-35 [17372046.001]
  • [Cites] Dig Dis Sci. 2007 Apr;52(4):1121-4 [17226074.001]
  • [Cites] Lancet. 2007 Jul 14;370(9582):114-6 [17630023.001]
  • [Cites] World J Gastroenterol. 2007 Aug 28;13(32):4372-8 [17708614.001]
  • [Cites] JAAPA. 2007 Sep;20(9):32-3, 35-6, 38 [17902540.001]
  • [Cites] Nat Clin Pract Gastroenterol Hepatol. 2008 Oct;5(10):569-82 [18797444.001]
  • (PMID = 20849628.001).
  • [ISSN] 1471-230X
  • [Journal-full-title] BMC gastroenterology
  • [ISO-abbreviation] BMC Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2949773
  •  go-up   go-down


85. Gaji F, Trecca A, Crispino P, Flati G: [Incidental diagnosis of caecum adenocarcinoma due to retention of endoscopic videocapsule: a clinical case]. Clin Ter; 2006 May-Jun;157(3):193-4
MedlinePlus Health Information. consumer health - Foreign Bodies.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Incidental diagnosis of caecum adenocarcinoma due to retention of endoscopic videocapsule: a clinical case].
  • [Transliterated title] Diagnosi incidentale di adenocarcinoma del cieco dovuto a ritenzione della videocapsula endoscopica: un caso clinico.
  • Capsule endoscopy is a new technique for the study of small intestine particularly in cases of obscure gastro-intestinal bleeding or chronic iron-deficiency anemia.
  • The patient was submitted to upper gastro-intestinal endoscopy and to partial colonscopy due to abdominal adhesions for previous abdominal surgery.
  • A capsule endoscopy was indicated to achieve a definitive diagnosis.
  • Wich discosed an intestinal obstruction.
  • [MeSH-major] Adenocarcinoma / diagnosis. Capsule Endoscopes. Cecal Neoplasms / diagnosis. Foreign Bodies / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16900842.001).
  • [ISSN] 0009-9074
  • [Journal-full-title] La Clinica terapeutica
  • [ISO-abbreviation] Clin Ter
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Letter
  • [Publication-country] Italy
  •  go-up   go-down


86. Marín García D, Cárdenas Lafuente F, Utrilla Ayala Mdel C, Galán Jurado MV, Jiménez Martín JJ, García Ordóñez MA: [Primary diffuse large B-cell lymphoma of the rectum simulating a rectal adenocarcinoma]. Gastroenterol Hepatol; 2010 Feb;33(2):92-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary diffuse large B-cell lymphoma of the rectum simulating a rectal adenocarcinoma].
  • [Transliterated title] Linfoma de tipo B difuso de células grandes primario rectal que simula un adenocarcinoma de recto.
  • Colorectal localization accounts for 15-20% of all gastrointestinal lymphomas, after the stomach and small intestine.
  • Dawson's criteria are highly useful in the differential diagnosis between primary colorectal involvement and gastrointestinal tract involvement secondary to systemic lymphoma, which is important due to the distinct prognosis and treatment of these entities.
  • [MeSH-major] Adenocarcinoma / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Rectal Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonoscopy. Cyclophosphamide / therapeutic use. Diagnosis, Differential. Doxorubicin / therapeutic use. Humans. Immunohistochemistry. Male. Meta-Analysis as Topic. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Prognosis. Radiography, Abdominal. Rectum / pathology. Tomography, X-Ray Computed. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier España, S.L. All rights reserved.
  • (PMID = 19875198.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


87. Manfredi S, Thiebot T, Henno S, Falize L, Bretagne JF, Meunier B: Complete response of an initially non-surgical adenocarcinoma of the duodenum to chemotherapy with the FOLFOX 4 regimen. J Gastrointest Surg; 2009 Dec;13(12):2309-13
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete response of an initially non-surgical adenocarcinoma of the duodenum to chemotherapy with the FOLFOX 4 regimen.
  • INTRODUCTION: The incidence of adenocarcinoma of the small bowel is very low in comparison with that of colorectal cancer.
  • No standard chemotherapy is defined for non-surgical adenocarcinoma of the small bowel.
  • CASE REPORT: We report here the case of a young patient with an initially non-surgical adenocarcinoma of the duodenum treated in a palliative setting with the FOLFOX 4 chemotherapy regimen.
  • CONCLUSION: The FOLFOX 4 regimen seems to be efficacious for some small-bowel adenocarcinomas and can be expected to lead to downstaging.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Duodenal Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19585173.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


88. Triantafillidis JK, Nasioulas G, Kosmidis PA: Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res; 2009 Jul;29(7):2727-37
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies.
  • Patients with long-standing ulcerative colitis and Crohn's disease have an increased risk of developing colorectal cancer and patients with small intestinal Crohn's disease are at increased risk of small bowel adenocarcinoma.
  • Colorectal cancer appearing on the ground of inflammatory bowel disease is the result of a process which is believed to begin from no dysplasia progressing to indefinite dysplasia, low-grade dysplasia, high-grade dysplasia and finally to invasive adenocarcinoma, although colorectal cancer can arise without proceeding through each of these steps.
  • [MeSH-major] Cell Transformation, Neoplastic. Colorectal Neoplasms / epidemiology. Inflammatory Bowel Diseases / epidemiology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19596953.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Number-of-references] 94
  •  go-up   go-down


89. Chan RC, Katelaris PH, Stewart P, Lin BP: Small bowel adenocarcinoma with high levels of microsatellite instability in Crohn's disease. Hum Pathol; 2006 May;37(5):631-4
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small bowel adenocarcinoma with high levels of microsatellite instability in Crohn's disease.
  • We report the case of a 26-year-old man, diagnosed 4 years earlier with Crohn's disease, who developed an associated small bowel adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Crohn Disease / pathology. Genomic Instability. Ileal Neoplasms / pathology. Microsatellite Repeats

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16647963.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


90. Xie J, Itzkowitz SH: Cancer in inflammatory bowel disease. World J Gastroenterol; 2008 Jan 21;14(3):378-89
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer in inflammatory bowel disease.
  • Patients with long-standing inflammatory bowel disease (IBD) have an increased risk of developing colorectal cancer (CRC).
  • Colon cancer risk in inflammatory bowel disease increases with longer duration of colitis, greater anatomic extent of colitis, the presence of primary sclerosing cholangitis, family history of CRC and degree of inflammation of the bowel.
  • Patients with small intestinal Crohn's disease are at increased risk of small bowel adenocarcinoma.
  • Other extra intestinal cancers, such as hepatobiliary and hematopoietic cancer, have shown variable incidence rates.
  • [MeSH-major] Colorectal Neoplasms / physiopathology. Inflammatory Bowel Diseases / physiopathology. Neoplasms / physiopathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 1999 Nov 1;18(21):5931-42 [10545105.001]
  • [Cites] Am J Gastroenterol. 1999 Nov;94(11):3248-53 [10566724.001]
  • [Cites] Am J Gastroenterol. 2002 Apr;97(4):922-7 [12008669.001]
  • [Cites] Dis Colon Rectum. 2002 May;45(5):615-20 [12004210.001]
  • [Cites] Aliment Pharmacol Ther. 2002 Jul;16(7):1225-32 [12144571.001]
  • [Cites] Arthritis Rheum. 2002 Dec;46(12):3151-8 [12483718.001]
  • [Cites] Gastroenterol Clin North Am. 2002 Dec;31(4):1133-44 [12489282.001]
  • [Cites] Dis Colon Rectum. 2003 Feb;46(2):156-9 [12576887.001]
  • [Cites] Gastroenterology. 2003 Apr;124(4):880-8 [12671882.001]
  • [Cites] Am J Surg Pathol. 1998 Mar;22(3):275-84 [9500769.001]
  • [Cites] Gut. 1998 May;42(5):711-4 [9659169.001]
  • [Cites] Dis Colon Rectum. 1998 Aug;41(8):992-6 [9715154.001]
  • [Cites] Gastroenterology. 1998 Nov;115(5):1079-83 [9797361.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Curr Opin Genet Dev. 1999 Feb;9(1):89-96 [10072354.001]
  • [Cites] Am J Gastroenterol. 1999 Apr;94(4):1047-52 [10201481.001]
  • [Cites] Am J Gastroenterol. 1999 Jun;94(6):1643-9 [10364038.001]
  • [Cites] Inflamm Bowel Dis. 2005 Mar;11(3):314-21 [15735438.001]
  • [Cites] Gut. 2005 May;54(5):617-22 [15831904.001]
  • [Cites] N Engl J Med. 2005 May 26;352(21):2184-92 [15917383.001]
  • [Cites] Am J Gastroenterol. 2005 Jun;100(6):1345-53 [15929768.001]
  • [Cites] Gut. 2005 Aug;54(8):1121-5 [16009685.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Oct;3(10):1015-21 [16234048.001]
  • [Cites] Gastroenterology. 2006 Apr;130(4):1030-8 [16618396.001]
  • [Cites] Gastroenterology. 2006 Jun;130(7):1941-9 [16762617.001]
  • [Cites] Endoscopy. 2006 May;38(5):477-82 [16767582.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Aug;4(8):1025-9 [16765651.001]
  • [Cites] Gastroenterol Clin North Am. 2006 Sep;35(3):553-71 [16952740.001]
  • [Cites] Gastroenterology. 1999 Dec;117(6):1288-94; discussion 1488-91 [10579969.001]
  • [Cites] Gastroenterology. 1999 Dec;117(6):1295-300 [10579970.001]
  • [Cites] Aliment Pharmacol Ther. 2000 Feb;14(2):145-53 [10651654.001]
  • [Cites] Gastrointest Endosc. 2000 Feb;51(2):123-8 [10650251.001]
  • [Cites] Biochim Biophys Acta. 2000 Feb 14;1470(1):M13-20 [10656986.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1773-9 [10793088.001]
  • [Cites] Gastroenterology. 2000 Jun;118(6):1018-24 [10833475.001]
  • [Cites] Am J Surg Pathol. 2000 Sep;24(9):1209-16 [10976694.001]
  • [Cites] Gut. 2000 Oct;47(4):514-9 [10986211.001]
  • [Cites] Gastroenterology. 2000 Nov;119(5):1219-27 [11054379.001]
  • [Cites] Dis Colon Rectum. 2000 Dec;43(12):1660-5 [11156448.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 May 9;92(10):4482-6 [7753829.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1169-70 [7577014.001]
  • [Cites] Am J Gastroenterol. 1995 Dec;90(12):2106-14 [8540497.001]
  • [Cites] Lancet. 1996 Jan 27;347(8996):215-9 [8551879.001]
  • [Cites] Leuk Lymphoma. 1995 Apr;17(3-4):255-62 [8580794.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Semin Diagn Pathol. 1996 Nov;13(4):339-57 [8946611.001]
  • [Cites] Gastroenterology. 1997 Jan;112(1):29-32 [8978339.001]
  • [Cites] Am J Gastroenterol. 1997 Feb;92(2):204-11 [9040192.001]
  • [Cites] Gastroenterology. 2003 Apr;124(4):889-93 [12671884.001]
  • [Cites] Clin Colorectal Cancer. 2003 May;3(1):47-53 [12777192.001]
  • [Cites] Gut. 2003 Aug;52(8):1127-32 [12865270.001]
  • [Cites] Colorectal Dis. 2003 Sep;5(5):490-5 [12925087.001]
  • [Cites] Gastroenterology. 2003 Nov;125(5):1311-9 [14598247.001]
  • [Cites] Inflamm Bowel Dis. 2003 Nov;9(6):351-5 [14671483.001]
  • [Cites] Gut. 2004 Feb;53(2):256-60 [14724160.001]
  • [Cites] Gastroenterology. 2004 Feb;126(2):451-9 [14762782.001]
  • [Cites] Inflamm Bowel Dis. 2004 Jan;10(1):32-5 [15058524.001]
  • [Cites] Gut. 2004 Jun;53(6):780-2 [15138201.001]
  • [Cites] Gut. 2004 Jun;53(6):849-53 [15138212.001]
  • [Cites] Gastroenterology. 2004 May;126(6):1634-48 [15168373.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Jul;2(7):534-41 [15224277.001]
  • [Cites] Scand J Gastroenterol. 1972;7(1):3-7 [5010506.001]
  • [Cites] Am J Surg. 1978 Jan;135(1):86-90 [623378.001]
  • [Cites] Gastroenterology. 1979 Aug;77(2):290-4 [447042.001]
  • [Cites] Gastroenterology. 1981 Feb;80(2):366-74 [7450425.001]
  • [Cites] Gut. 1982 Jun;23(6):490-7 [7076024.001]
  • [Cites] Dig Dis Sci. 1983 Jan;28(1):18-26 [6822178.001]
  • [Cites] Hum Pathol. 1983 Nov;14(11):931-68 [6629368.001]
  • [Cites] Br J Surg. 1985 Sep;72 Suppl:S84-6 [3899269.001]
  • [Cites] Cancer. 1985 Dec 15;56(12):2914-21 [4052961.001]
  • [Cites] Cancer. 1986 Oct 1;58(7):1569-74 [3742475.001]
  • [Cites] Histopathology. 1988 Oct;13(4):385-97 [3220464.001]
  • [Cites] Scand J Gastroenterol. 1989 Apr;24(3):346-50 [2734593.001]
  • [Cites] Gastroenterology. 1989 Aug;97(2):255-9 [2568304.001]
  • [Cites] Hum Pathol. 1989 Oct;20(10):1008-14 [2793156.001]
  • [Cites] Gut. 1990 Jul;31(7):800-6 [2370015.001]
  • [Cites] N Engl J Med. 1990 Nov 1;323(18):1228-33 [2215606.001]
  • [Cites] Cancer. 1991 Apr 1;67(7):2015-9 [2004319.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1787-90 [9065402.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 1997 Feb;24(2):202-10 [9106108.001]
  • [Cites] Gastroenterology. 1997 May;112(5):1487-92 [9136826.001]
  • [Cites] Gut. 1997 Oct;41(4):522-5 [9391253.001]
  • [Cites] Ann Intern Med. 2001 Jan 16;134(2):89-95 [11177311.001]
  • [Cites] Gut. 2001 Mar;48(3):430-4 [11171838.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):854-62 [11241255.001]
  • [Cites] Gut. 2001 Apr;48(4):526-35 [11247898.001]
  • [Cites] Gastroenterology. 2001 Mar;120(4):820-6 [11231935.001]
  • [Cites] Gastroenterology. 2001 Mar;120(4):841-7 [11231938.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):687-92 [11257100.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):721-33 [11257105.001]
  • [Cites] Gastroenterology. 2001 May;120(6):1356-62 [11313305.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3573-7 [11325821.001]
  • [Cites] J Pathol. 2001 Jun;194(2):152-7 [11400142.001]
  • [Cites] Aliment Pharmacol Ther. 2001 Aug;15(8):1101-8 [11472312.001]
  • [Cites] Gastroenterology. 2001 Aug;121(2):275-81 [11487537.001]
  • [Cites] Aliment Pharmacol Ther. 2001 Dec;15(12):1843-9 [11736713.001]
  • [Cites] Gastroenterology. 2002 Mar;122(3):606-13 [11874992.001]
  • [Cites] Mod Pathol. 2002 Apr;15(4):379-86 [11950911.001]
  • [Cites] Gastroenterology. 1991 May;100(5 Pt 1):1241-8 [2013371.001]
  • [Cites] Int J Epidemiol. 1991 Jun;20(2):368-74 [1917236.001]
  • [Cites] Cancer. 1992 Mar 1;69(5):1119-23 [1739911.001]
  • [Cites] Gastroenterology. 1992 Aug;103(2):431-8 [1634062.001]
  • [Cites] Gut. 1992 Jul;33(7):938-41 [1644333.001]
  • [Cites] Gastroenterology. 1992 Nov;103(5):1611-20 [1426881.001]
  • [Cites] J Natl Cancer Inst. 1993 Jun 2;85(11):875-84 [8492316.001]
  • [Cites] Gastroenterology. 1993 Aug;105(2):418-24 [8335197.001]
  • [Cites] Gastroenterology. 1993 Dec;105(6):1716-23 [8253348.001]
  • [Cites] Lancet. 1994 Jan 8;343(8889):71-4 [7903776.001]
  • [Cites] Z Gastroenterol. 1993 Nov;31(11):653-6 [8291276.001]
  • [Cites] Gut. 1994 Mar;35(3):347-52 [8150345.001]
  • [Cites] Lancet. 1994 May 21;343(8908):1249-52 [7910274.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):934-44 [7926483.001]
  • [Cites] Gastroenterology. 1994 Dec;107(6):1675-9 [7958678.001]
  • [Cites] Gut. 1994 Nov;35(11):1507-8 [7828962.001]
  • [Cites] Int J Cancer. 1995 Jan 27;60(3):330-3 [7829239.001]
  • [Cites] Gastroenterology. 1995 May;108(5):1361-70 [7729627.001]
  • (PMID = 18200660.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 118
  • [Other-IDs] NLM/ PMC2679126
  •  go-up   go-down


91. Kersting S, Bruewer M, Laukoetter MG, Rijcken EM, Mennigen R, Buerger H, Senninger N, Krieglstein CF: Intestinal cancer in patients with Crohn's disease. Int J Colorectal Dis; 2007 Apr;22(4):411-7
MedlinePlus Health Information. consumer health - Crohn's Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal cancer in patients with Crohn's disease.
  • BACKGROUND: Surveillance of intestinal cancer in Crohn's disease (CD) has often been advocated.
  • To date, no clear evidence exists whether CD patients are at special risk for intestinal cancer.
  • An increased incidence of small bowel adenocarcinoma is suggested.
  • We report our experience with 10 cases of CD complicated by intestinal adenocarcinoma.
  • Data of patients that developed carcinoma within Crohn's lesions of either small or large bowel were analyzed.
  • Mean age at the time of diagnosis of CD was 43 years.
  • Mean duration of CD until diagnosis of cancer was 14 years.
  • Delayed diagnosis resulted in a poor prognosis.
  • [MeSH-major] Crohn Disease / complications. Intestinal Neoplasms / etiology
  • [MeSH-minor] Adult. Colorectal Neoplasms. Databases, Factual. Female. Humans. Ileitis. Incidence. Intestinal Fistula. Male. Middle Aged. Survival Rate

  • Genetic Alliance. consumer health - Crohn Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16847674.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


92. Sakai Y, Tsuyuguchi T, Ohara T, Yukisawa S, Tsuchiya S, Sugiyama H, Miyakhawa K, Ohbu M, Kato K, Kimura M, Kaiho T, Takeuchi O, Matsuzaki O, Miyazaki M, Yokosuka O: A patient with adenocarcinoma of the jejunum successfully diagnosed by preoperative endoscopy for the small intestine. Hepatogastroenterology; 2008 Jul-Aug;55(85):1367-9
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A patient with adenocarcinoma of the jejunum successfully diagnosed by preoperative endoscopy for the small intestine.
  • In this study, the authors report the case of a 35-year-old man diagnosed preoperatively as having adenocarcinoma of the jejunum using a conventional endoscopy, usually used for the examination of the large intestine.
  • [MeSH-major] Adenocarcinoma / pathology. Endoscopy. Jejunal Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Ileus / diagnosis. Ileus / etiology. Ileus / surgery. Intestine, Small. Male

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18795691.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


93. von Rahden BH, Langner C, Brücher BL, Stein HJ, Sarbia M: No association of primary adenocarcinomas of the small bowel with Epstein-Barr virus infection. Mol Carcinog; 2006 May;45(5):349-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No association of primary adenocarcinomas of the small bowel with Epstein-Barr virus infection.
  • Adenocarcinomas of the small bowel comprise a very rare entity, with little knowledge about molecular properties and etiological aspects.
  • We have investigated the prevalence of EBER expression (EBV-encoded small RNAs) in a series of small bowel adenocarcinomas (n=56) utilizing RNA in situ hybridization (EBER-RISH).
  • A surgical series of 82 primary resected gastric (n=36) or cardiac (n=46) adenocarcinomas (TU Munich) was used as control group.
  • None of the 56 small bowel carcinomas exhibited EBER expression whereas in the control group the rate of EBER expression accounted for 4.4% in the group of cardia carcinomas and 8.6% in the group of gastric cancers.
  • These results indicate that EBV infection plays no etiologic role in primary small bowel adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / virology. Epstein-Barr Virus Infections / virology. Herpesvirus 4, Human / genetics. Intestinal Neoplasms / virology. Intestine, Small / virology. Stomach Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16493667.001).
  • [ISSN] 0899-1987
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Viral
  •  go-up   go-down


94. Zar N, Garmo H, Holmberg L, Hellman P: Risk of second primary malignancies and causes of death in patients with adenocarcinoma and carcinoid of the small intestine. Eur J Cancer; 2008 Mar;44(5):718-25
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of second primary malignancies and causes of death in patients with adenocarcinoma and carcinoid of the small intestine.
  • We studied risk of second malignancies and causes of death in 1829 cases of adenocarcinoma and 3055 cases of carcinoid tumours in the small bowel reported to the Swedish Cancer Registry from 1960 through to 2000.
  • Female patients with adenocarcinoma had increased risk of acquiring cancer in the female genital organs (SIR 3.2; 95% confidence intervals (CI) 1.9-5.0) and breasts (SIR 2.7; 95% CI 1.1-5.4).
  • Patients with adenocarcinoma had increased risk of dying from malignant diseases other than the primary cancer (SMR 9.5; 95% CI 8.6-10) and gastrointestinal disease (SMR 2.6 95% CI 1.6-4.2).
  • A detailed analysis of causes of death in a population-based cohort of small intestinal malignancies has not been presented before in the literature.
  • [MeSH-major] Adenocarcinoma / mortality. Carcinoid Tumor / mortality. Intestinal Neoplasms / mortality. Intestine, Small. Neoplasms, Second Primary / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18207733.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


95. Langholz E: Current trends in inflammatory bowel disease: the natural history. Therap Adv Gastroenterol; 2010 Mar;3(2):77-86

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current trends in inflammatory bowel disease: the natural history.
  • The description of the prognosis of inflammatory bowel disease (IBD) is based on systematic follow-up of population-based cohorts.
  • One-third of Crohn's disease (CD) patients present with colonic disease, one-third with ileocolonic disease and one-third with small bowel disease.
  • IBD is associated with extra-intestinal manifestations (EIMs) in up to 36% of patients.
  • At diagnosis behaviour is inflammatory in 70% of patients.
  • Patients with small bowel CD are also at increased risk of small bowel adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21180592.001).
  • [ISSN] 1756-2848
  • [Journal-full-title] Therapeutic advances in gastroenterology
  • [ISO-abbreviation] Therap Adv Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3002570
  • [Keywords] NOTNLM ; colorectal cancer / disease course / epidemiology / inflammatory bowel disease / mortality / prognosis
  •  go-up   go-down


96. Schottenfeld D, Beebe-Dimmer JL, Vigneau FD: The epidemiology and pathogenesis of neoplasia in the small intestine. Ann Epidemiol; 2009 Jan;19(1):58-69
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The epidemiology and pathogenesis of neoplasia in the small intestine.
  • PURPOSE: The mucosa of the small intestine encompasses about 90% of the luminal surface area of the digestive system, but only 2% of the total annual gastrointestinal cancer incidence in the United States.
  • METHODS: The remarkable contrast in age-standardized cancer incidence between the small and large intestine has been reviewed with respect to the cell type patterns, demographic features, and molecular characteristics of neoplasms.
  • RESULTS: Particularly noteworthy is the predominance of adenocarcinoma in the colon, which exceeds 98% of the total incidence by cell type, in contrast to that of 30% to 40% in the small intestine, resulting in an age-standardized ratio of rates exceeding 50-fold.
  • The positive correlation in global incidence rates of small and large intestinal neoplasms and the reciprocal increases in risk of second primary adenocarcinomas suggest that there are common environmental risk factors.
  • The pathophysiology of Crohn inflammatory bowel disease and the elevated risk of adenocarcinoma demonstrate the significance of the impaired integrity of the mucosal barrier and of aberrant immune responses to luminal indigenous and potentially pathogenic microorganisms.
  • CONCLUSION: In advancing a putative mechanism for the contrasting mucosal susceptibilities of the small and large intestine, substantial differences are underscored in the diverse taxonomy, concentration and metabolic activity of anaerobic organisms, rate of intestinal transit, changing pH, and the enterohepatic recycling and metabolism of bile acids.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Immunol. 2002 Jan;2(1):37-45 [11905836.001]
  • [Cites] Gastroenterology. 2002 Apr;122(4):854-66 [11910336.001]
  • [Cites] Gut. 2002 May;50(5):647-52 [11950810.001]
  • [Cites] Hum Pathol. 2002 Mar;33(3):322-9 [11979373.001]
  • [Cites] Am J Gastroenterol. 2002 Jun;97(6):1421-8 [12094860.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1428-35 [12404215.001]
  • [Cites] Lancet Oncol. 2003 Jan;4(1):22-9 [12517536.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:13-27 [15153416.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:199-208 [15153435.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:218-9 [15153437.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):117-22 [15213627.001]
  • [Cites] Cancer Res. 1974 Sep;34(9):2368-72 [4843537.001]
  • [Cites] Clin Gastroenterol. 1977 Jan;6(1):3-24 [330051.001]
  • [Cites] Am J Surg. 1978 Jan;135(1):86-90 [623378.001]
  • [Cites] Cancer Res. 1981 Apr;41(4):1363-7 [7194137.001]
  • [Cites] Dis Colon Rectum. 1987 Oct;30(10):790-9 [3308369.001]
  • [Cites] Cancer. 1989 Nov 15;64(10):2178-83 [2804907.001]
  • [Cites] J Natl Cancer Inst. 1990 Apr 18;82(8):650-61 [2157027.001]
  • [Cites] Mutat Res. 1990 May;238(3):313-20 [2188127.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Aug;8(8):715-9 [10744132.001]
  • [Cites] Cancer Lett. 2000 Oct 16;159(1):73-8 [10974408.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 1;92(21):1740-52 [11058617.001]
  • [Cites] Cancer Causes Control. 2000 Oct;11(9):791-7 [11075867.001]
  • [Cites] Gastroenterology. 2000 Dec;119(6):1447-53 [11113065.001]
  • [Cites] Cancer Causes Control. 2001 Jan;12(1):13-21 [11227921.001]
  • [Cites] Int J Biochem Cell Biol. 2001 Feb;33(2):193-203 [11240376.001]
  • [Cites] Int J Cancer. 1999 Jul 19;82(2):171-4 [10389747.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2010-6 [10445521.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2128-34 [10445539.001]
  • [Cites] Fed Proc. 1964 Nov-Dec;23:1386-8 [14236160.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):162-8 [15654796.001]
  • [Cites] Gastroenterology. 2005 Mar;128(3):590-9 [15765394.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):251-62 [15803153.001]
  • [Cites] Gastroenterology. 2005 Apr;128(4 Suppl 1):S47-51 [15825126.001]
  • [Cites] Gastroenterology. 2005 Apr;128(4 Suppl 1):S57-67 [15825128.001]
  • [Cites] Am J Gastroenterol. 2005 May;100(5):1134-42 [15842590.001]
  • [Cites] Nat Rev Genet. 2005 May;6(5):376-88 [15861209.001]
  • [Cites] Cell Mol Life Sci. 2005 Apr;62(7-8):791-9 [15868404.001]
  • [Cites] Gastroenterol Clin North Am. 2005 Sep;34(3):401-12, vii-viii [16084304.001]
  • [Cites] Gastroenterol Clin North Am. 2005 Sep;34(3):437-50, viii [16084306.001]
  • [Cites] Cancer Causes Control. 2005 Sep;16(7):781-7 [16132788.001]
  • [Cites] Br J Cancer. 2005 Oct 3;93(7):807-10 [16175183.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):189-96 [16003748.001]
  • [Cites] Ann Intern Med. 2005 Dec 20;143(12):895-904 [16365470.001]
  • [Cites] Am J Gastroenterol. 2005 Dec;100(12):2724-9 [16393226.001]
  • [Cites] Annu Rev Med. 2006;57:207-21 [16409146.001]
  • [Cites] Lancet Oncol. 2006 Feb;7(2):149-56 [16455479.001]
  • [Cites] Hum Mol Genet. 2006 Mar 15;15(6):1015-23 [16461335.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):69-83 [16514135.001]
  • [Cites] Clin Microbiol Rev. 2006 Apr;19(2):315-37 [16614252.001]
  • [Cites] Gastroenterology. 2006 Apr;130(4):1039-46 [16618397.001]
  • [Cites] Lancet. 2006 Apr 15;367(9518):1271-84 [16631883.001]
  • [Cites] J Natl Cancer Inst. 2006 Jul 5;98(13):920-31 [16818856.001]
  • [Cites] J Natl Cancer Inst. 2006 Jul 5;98(13):936-9 [16818858.001]
  • [Cites] Gastroenterol Clin North Am. 2006 Sep;35(3):621-39 [16952744.001]
  • [Cites] Lab Invest. 2006 Oct;86(10):1052-63 [16909128.001]
  • [Cites] J Natl Cancer Inst. 2006 Sep 20;98(18):1321-30 [16985251.001]
  • [Cites] Ann N Y Acad Sci. 2006 Aug;1072:9-18 [17057186.001]
  • [Cites] Ann N Y Acad Sci. 2006 Aug;1072:135-54 [17057196.001]
  • [Cites] Ann N Y Acad Sci. 2006 Aug;1072:321-31 [17057212.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2069-77 [17119030.001]
  • [Cites] Carcinogenesis. 2007 Jan;28(1):215-22 [16887864.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2551-7 [17167138.001]
  • [Cites] World J Gastroenterol. 2007 Jan 7;13(1):146-51 [17206762.001]
  • [Cites] Annu Rev Med. 2007;58:401-16 [16987083.001]
  • [Cites] Cancer. 2007 Jun 15;109(12):2420-31 [17469181.001]
  • [Cites] Nat Rev Cancer. 2007 Aug;7(8):599-612 [17646865.001]
  • [Cites] Int J Cancer. 2007 Dec 1;121(11):2381-6 [17893868.001]
  • [Cites] Clin Microbiol Rev. 2007 Oct;20(4):593-621 [17934076.001]
  • [Cites] Gastroenterol Clin North Am. 2007 Sep;36(3):499-513, vii [17950435.001]
  • [Cites] Gastroenterol Clin North Am. 2007 Dec;36(4):927-46, viii [17996798.001]
  • [Cites] Annu Rev Pathol. 2007;2:401-29 [18039105.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2533-47 [18086756.001]
  • [Cites] Gastroenterology. 2008 Jan;134(1):306-23 [18166359.001]
  • [Cites] Lancet Oncol. 2008 Jan;9(1):61-72 [18177818.001]
  • [Cites] Am J Gastroenterol. 2008 Jan;103(1):190-5 [18184122.001]
  • [Cites] Gastroenterology. 2008 Feb;134(2):388-95 [18242207.001]
  • [Cites] Gastroenterology. 2008 Feb;134(2):577-94 [18242222.001]
  • [Cites] Br J Cancer. 2008 Feb 26;98(4):684-8 [18253129.001]
  • [Cites] J Surg Oncol. 2008 Mar 15;97(4):350-9 [18286477.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cancer Causes Control. 2002 Feb;13(1):27-34 [11899115.001]
  • [Cites] JAMA. 2002 Mar 20;287(11):1413-9 [11903028.001]
  • [Cites] Gut. 2001 Apr;48(4):526-35 [11247898.001]
  • [Cites] Gut. 2001 Apr;48(4):536-41 [11247899.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):721-33 [11257105.001]
  • [Cites] Glycobiology. 2001 Feb;11(2):1R-10R [11287395.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1803-8 [11337378.001]
  • [Cites] Nature. 2001 May 31;411(6837):599-603 [11385576.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):542-7 [11522737.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2017-22 [11733352.001]
  • [Cites] Annu Rev Pathol. 2008;3:557-86 [18039140.001]
  • [Cites] Int J Cancer. 2008 Aug 15;123(4):867-73 [18491401.001]
  • [Cites] Gut. 2002 Feb;50(2):218-23 [11788563.001]
  • [Cites] Oncogene. 2002 Jan 3;21(1):158-64 [11791187.001]
  • [Cites] Arch Pharm Res. 2001 Dec;24(6):564-7 [11794536.001]
  • [Cites] Lancet. 2002 Jan 5;359(9300):62-9 [11809204.001]
  • [Cites] Am J Hum Genet. 2002 Apr;70(4):845-57 [11875755.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Mar;7(3):243-51 [9521441.001]
  • [Cites] Am J Epidemiol. 1998 May 15;147(10):903-10 [9596467.001]
  • [Cites] Gastroenterology. 2002 Jan;122(1):44-54 [11781279.001]
  • [Cites] Dis Colon Rectum. 2002 Jan;45(1):91-7 [11786770.001]
  • [Cites] Lancet. 2003 Feb 8;361(9356):512-9 [12583961.001]
  • [Cites] Lancet. 2003 Apr 12;361(9365):1290-2 [12699968.001]
  • [Cites] Arch Intern Med. 2003 Jul 14;163(13):1566-72 [12860579.001]
  • [Cites] Lancet. 2003 Aug 2;362(9381):383-91 [12907013.001]
  • [Cites] Am J Med. 2003 Aug 15;115(3):191-5 [12935825.001]
  • [Cites] Surg Oncol. 2003 Aug;12(2):153-72 [12946486.001]
  • [Cites] Int J Cancer. 2003 Nov 1;107(2):171-6 [12949790.001]
  • [Cites] Am J Clin Nutr. 2003 Oct;78(4):675-83 [14522724.001]
  • [Cites] N Engl J Med. 2004 Jan 15;350(3):239-48 [14724303.001]
  • [Cites] Cancer. 2004 Feb 1;100(3):524-30 [14745868.001]
  • [Cites] J Nutr. 2004 Feb;134(2):459-64 [14747689.001]
  • [Cites] Cancer Causes Control. 2004 Feb;15(1):35-43 [14970733.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:1-12 [15153415.001]
  • [Cites] Cancer. 1990 Aug 15;66(4):702-15 [2167140.001]
  • [Cites] Br J Cancer. 1991 Jan;63(1):143-5 [1989654.001]
  • [Cites] Surg Gynecol Obstet. 1991 Nov;173(5):343-9 [1948581.001]
  • [Cites] Gastroenterology. 1992 Jun;102(6):1980-2 [1316858.001]
  • [Cites] Gut. 1992 Sep;33(9):1239-45 [1427378.001]
  • [Cites] Nutr Cancer. 1992;18(2):97-111 [1437657.001]
  • [Cites] Cancer Causes Control. 1993 Mar;4(2):163-9 [8481495.001]
  • [Cites] Dis Colon Rectum. 1993 Jul;36(7):654-61 [8348849.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1993 Nov-Dec;2(6):551-3 [8268772.001]
  • [Cites] Br J Surg. 1994 Jan;81(1):20-4 [8313111.001]
  • [Cites] Am J Gastroenterol. 1994 May;89(5):699-701 [8172140.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Apr-May;3(3):205-7 [8019367.001]
  • [Cites] Gut. 1994 Aug;35(8):1090-7 [7926912.001]
  • [Cites] Br J Surg. 1994 Dec;81(12):1722-33 [7827926.001]
  • [Cites] Scand J Gastroenterol. 1996 Apr;31(4):376-82 [8726307.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Feb;5(2):81-4 [8850266.001]
  • [Cites] Int J Epidemiol. 1996 Aug;25(4):722-8 [8921448.001]
  • [Cites] Int J Cancer. 1997 Mar 4;70(5):512-7 [9052748.001]
  • [Cites] Cancer Res. 1997 Mar 15;57(6):1098-102 [9067278.001]
  • [Cites] Cancer. 1997 May 1;79(9):1804-8 [9128999.001]
  • [Cites] Gastroenterology. 1997 Jul;113(1):127-35 [9207270.001]
  • [Cites] Ann Intern Med. 1997 Sep 15;127(6):423-8 [9312998.001]
  • [Cites] Nat Genet. 1998 Jan;18(1):38-43 [9425897.001]
  • [Cites] Ann Intern Med. 1998 Jun 1;128(11):896-9 [9634427.001]
  • [Cites] Cancer. 1998 Jul 15;83(2):240-4 [9669805.001]
  • [Cites] J Pathol. 1998 Jun;185(2):119-22 [9713336.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5267-70 [9850045.001]
  • [Cites] Am J Clin Nutr. 1999 Mar;69(3):354-65 [10075317.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1664-9 [10223558.001]
  • [Cites] Am J Gastroenterol. 1999 May;94(5):1139-52 [10235185.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Dec;8(12):1101-5 [10613343.001]
  • [Cites] Cancer Causes Control. 2000 Feb;11(2):145-50 [10710198.001]
  • (PMID = 19064190.001).
  • [ISSN] 1873-2585
  • [Journal-full-title] Annals of epidemiology
  • [ISO-abbreviation] Ann Epidemiol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K07 CA127214; United States / NCI NIH HHS / CA / N01PC35145; United States / NCI NIH HHS / CA / 1K07CA127214-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines
  • [Number-of-references] 151
  • [Other-IDs] NLM/ NIHMS521424; NLM/ PMC3792582
  •  go-up   go-down


97. Napolitano L, de Nicola P, Di Bartolomeo N, Aceto L, Liddo G, Angelucci D, Innocenti P: [A case of perforated small bowel adenocarcinoma as first symptom of Crohn's disease]. G Chir; 2005 May;26(5):212-4
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of perforated small bowel adenocarcinoma as first symptom of Crohn's disease].
  • [Transliterated title] Adenocarcinoma perforato del piccolo intestino come prima evidente manifestazione del morbo di Crohn: case report.
  • A case of perforated small bowel adenocarcinoma presenting as first symptom of Crohn's disease is reported in a 53 years old male patient with abdominal pain and alteration of bowel habits.
  • [MeSH-major] Adenocarcinoma / complications. Crohn Disease / diagnosis. Ileal Neoplasms / complications. Intestinal Perforation / etiology

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16184705.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


98. Khelifi S, Bouhafa A, Agrebi W, Cherif A, Ben M, Khayat O, Letaief A: [Filiation hamartoma polyposis dysplasia and small bowel adenocarcinoma]. Tunis Med; 2006 Feb;84(2):128-30
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Filiation hamartoma polyposis dysplasia and small bowel adenocarcinoma].
  • Transformation of the polyposis hamartoma into a site of dysplasia then into adenocarcinoma has been rarely reported.
  • [MeSH-major] Adenocarcinoma / complications. Ileal Neoplasms / complications. Peutz-Jeghers Syndrome / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16755980.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


99. Oscarson M, Burk O, Winter S, Schwab M, Wolbold R, Dippon J, Eichelbaum M, Meyer UA: Effects of rifampicin on global gene expression in human small intestine. Pharmacogenet Genomics; 2007 Nov;17(11):907-18
Hazardous Substances Data Bank. RIFAMPIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of rifampicin on global gene expression in human small intestine.
  • OBJECTIVES: The small intestinal wall serves as an important barrier for the entry of foreign substances into the organism.
  • Some of the genes encoding these proteins are transcriptionally activated by xenobiotics, a response well studied in liver but less so in the intestine.
  • The effect of the inducer drug rifampicin on intestinal cells was therefore evaluated both in vivo and in vitro.
  • The gene expression profile was also assessed in LS174T cells derived from a human colon adenocarcinoma after exposure to 10 micromol/l rifampicin for 24 h.
  • The list of rifampicin regulated transcripts expectedly included drug metabolizing enzymes and drug transporters, but also genes involved in lipid and amino acid metabolism as well as genes not previously recognized to be part of the adaptation of intestinal cells to xenobiotic exposure.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Biomarkers / metabolism. Colonic Neoplasms / drug therapy. Colonic Neoplasms / metabolism. Colonic Neoplasms / pathology. Gene Expression Profiling. Humans. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Transcription, Genetic / drug effects. Transcription, Genetic / genetics. Tumor Cells, Cultured / drug effects. Tumor Cells, Cultured / metabolism. Tumor Cells, Cultured / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18075461.001).
  • [ISSN] 1744-6872
  • [Journal-full-title] Pharmacogenetics and genomics
  • [ISO-abbreviation] Pharmacogenet. Genomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antitubercular; 0 / Biomarkers; 0 / RNA, Messenger; VJT6J7R4TR / Rifampin
  •  go-up   go-down


100. Prodinger PM, Sarbia M, Massmann J, Straka C, Meyer G, Steinlein OK: Gorlin syndrome associated with small bowel carcinoma and mesenchymal proliferation of the gastrointestinal tract: case report and review of literature. BMC Cancer; 2010;10:360
Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gorlin syndrome associated with small bowel carcinoma and mesenchymal proliferation of the gastrointestinal tract: case report and review of literature.
  • BACKGROUND AND CASE PRESENTATION: A patient with nevoid basal cell carcinoma syndrome (Gorlin syndrome) presented with two unusual clinical features, i.e. adenocarcinoma of the small bowel and extensive mesenchymal proliferation of the lower gastrointestinal tract.
  • [MeSH-major] Basal Cell Nevus Syndrome / pathology. Cell Proliferation. Gastrointestinal Tract / pathology. Intestinal Neoplasms / pathology. Intestine, Small / pathology. Mesoderm / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Mol Life Sci. 2000 Nov;57(12):1720-31 [11130178.001]
  • [Cites] Mod Pathol. 2001 Nov;14(11):1141-6 [11706076.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] J Pathol. 2004 Aug;203(4):909-17 [15258993.001]
  • [Cites] J Pediatr Surg. 2007 Dec;42(12):2080-5 [18082712.001]
  • [Cites] J Dermatol. 1997 Feb;24(2):117-9 [9065708.001]
  • [Cites] Am J Med Genet. 1997 Mar 31;69(3):299-308 [9096761.001]
  • [Cites] N Engl J Med. 1960 May 5;262:908-12 [13851319.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19879-84 [18077420.001]
  • [Cites] Nature. 1996 Nov 14;384(6605):129-34 [8906787.001]
  • (PMID = 20609239.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Cell Surface; 0 / patched receptors
  • [Other-IDs] NLM/ PMC2912266
  •  go-up   go-down






Advertisement